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Supervisor:  Nikolaos (Nicholas) A. Peppas 
 
A composite platform strategy for oral vaccination with subunit antigens was 
developed to improve i) ease of administration and distribution; and ii) induction of 
mucosal immunity. The platform is referred to as Polyanhdyride-Releasing MicroParticle 
Technology, or PROMPT.  In its core, polyanhydride nanoparticles based on 1,6-bis-(p-
carboxyphenoxy)hexane (CPH) and sebacic acid (SA) served simultaneously as adjuvant 
and delivery vehicle of subunit antigens, while microencapsulation by pH-responsive 
polymers based on poly(ethylene glycol) (PEG) and poly(methacrylic acid) (PMAA) 
enabled targeted intestinal delivery of the nanoparticle payload. PROMPT formulations 
were synthesized by pH-mediated self-assembly to encapsulate nanoparticles. The 
reversible pH-responsive transition of these formulations coincided with the pH transition 
experienced during intestinal delivery, such that particles dissociated to release 
nanoparticles above pH 5. The physicochemical characteristics of the composite 
microgels were evaluated by Fourier transform infrared spectroscopy, electron 
microscopy, and confocal microscopy. PROMPT formulations demonstrated pH-
dependent burst release of the encapsulated model antigen, ovalbumin, and then sustained 
release thereafter in both neutral pH and simulated gastrointestinal conditions. The 
biocompatibility and immunostimulatory capabilities of PROMPT formulations were 
 viii 
evaluated in relevant cell lines to identify lead candidates for in vivo immunization 
experiments. PROMPT composite formulations demonstrated greater than 85% viability 
at microgel concentrations less than 1mg/mL, as indicated by cellular proliferation and 
membrane integrity. PROMPT microgels also demonstrated the ability to activate bone 
marrow-derived dendritic cells in vitro by stimulating cell surface marker expression and 
cytokine secretion. Finally, the ability of lead formulations to elicit immune responses 
was assessed in vivo by administering PROMPT formulations to BALB/c mice by oral 
gavage. PROMPT formulations induced measurable ovalbumin-specific IgA and IgG in 
mucosal fluids and blood serum, respectively, while soluble antigen and nanoparticles 
alone did not. This work shows that microencapsulation of nanoparticles for oral vaccine 
administration is a promising platform for developing safe, effective subunit-based 
vaccines.   
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Chapter 1: Introduction1 
Vaccines have reduced substantially the burden of infectious disease, second only 
to clean drinking water in reducing mortality worldwide (1). Immunization is a cost 
effective strategy that protects not only the vaccinated individuals, but can indirectly 
protect the surrounding community through the generation of herd immunity (2).  
Development of vaccines against a variety of diseases, including diphtheria, 
tetanus, polio, measles, mumps, rubella, hepatitis B, and meningitis, have reduced the 
associated mortality by 97-99% (3).  However, even with multiple successful vaccination 
campaigns, infectious diseases remain the second leading cause of death worldwide, 
disproportionately affecting children under the age of 5 and people in low income 
countries (4). In fact, five of the top ten leading causes of death in low income countries 
are caused by infectious agents: lower respiratory infections (e.g. pneumonia), 
HIV/AIDS, diarrheal disease, malaria, and tuberculosis. While some of these pathogens 
currently lack a vaccine necessary for disease control, an estimated 20% of these deaths 
result from vaccine-preventable diseases, indicating the need for substantial improvement 
in vaccine technology and administration (4-6). 
The majority of infections occurs after crossing one of the body’s numerous 
protective mucosal barriers (5, 7, 8). For example, potentially fatal diarrheal diseases are 
often caused by enteropathogens crossing the mucosal barrier of the GI tract after 
ingestion of contaminated water (9). The formation of an immunologically strong 
mucosal barrier would be an effective strategy to prevent infection at the point of contact 
between microbes and the host. However, the current standards of vaccine technology 
                                                 
1  J. Vela Ramirez, L. Sharpe, and N.A. Peppas. Current State and Challenges in Developing Oral 
Vaccines. Adv. Drug Deliv. Rev. 2017, In Press. Vela Ramirez and Sharpe contributed equally to the 
review article and Peppas oversaw the project. 
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typically only address pathogens that have already bypassed a mucosal barrier. The 
majority of licensed vaccines are administered either by subcutaneous or intramuscular 
injection. The resulting immune response is generally limited to systemic humoral 
immunity (e.g. antibody production) against the pathogen or toxin, with limited cellular 
immunity (e.g. T cell-mediated), and only weak protection generated at the mucosal 
surfaces (10, 11). In contrast, vaccination at mucosal surfaces successfully induces 
mucosal antibodies (IgA) and cell-mediated immune responses, while still producing a 
systemic antibody response (IgG) (12-15).   
The largest mucosal surface in the body, the GI tract, is readily accessible via oral 
administration. The oral delivery of therapeutic drugs represents the current gold standard 
of administration due to the opportunity for self-administration, improved patient 
compliance, and the ease of distribution compared to injection-based therapies (16-19). 
Additionally, vaccine efficacy is highly correlated to its regional coverage, which is 
affected by the accessibility, stability, and distribution of the formulation (2, 20). 
Consideration of these parameters is important in the development of next-generation 
vaccines. 
Unfortunately, despite the numerous immunological and practical advantages 
associated with oral delivery, only a limited number of oral vaccines are available (21, 
22). The oral route poses obstacles, including degradation of fragile antigens through the 
harsh environment in the stomach, requirement of higher doses to generate immunity 
instead of tolerance, and surpassing physicochemical defense mechanisms of the mucosa 
to stimulate immune response (21, 23). Each challenge within the GI tract poses a unique 
engineering problem that requires careful consideration to achieve efficacious vaccine 
design. 
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The use of biodegradable polymeric particles for antigen delivery has gained 
attention as a strategy to prevent degradation of immunogens in the GI tract (24, 25). 
Polymeric materials can be manipulated based on chemical characteristics in order to 
tailor release kinetics of the encapsulated payload, direct responsiveness to the local 
environment (e.g. pH), and provide immune stimulation (23, 26, 27). Specifically, 
polyanhydrides are a family of biodegradable polymers with desirable properties for 
novel drug and antigen delivery platforms (25, 28, 29). Polyanhydrides are hydrophobic 
materials that undergo surface-erosion, and have been demonstrated to stabilize various 
types of antigens (i.e. proteins, peptides), sustain antigen release, and degrade into 
biocompatible products (25, 28-30). Furthermore, polyanhydrides possess adjuvant 
properties and can stimulate both humoral and cellular immune responses (31-33).  
The encapsulation of nanoparticle in microspheres has been explored for oral 
delivery applications, which require cellular uptake for efficacy (34-38). A polymeric 
coating can improve nanoparticle stability in contact with physiological fluids in the 
gastrointestinal tract until reaching the absorptive window in the intestinal epithelium and 
then enable depot delivery of the nanoparticle cargo. A class of pH-responsive 
complexation hydrogels, based on methacrylic acid (MAA) has been designed to 
facilitate transmucosal administration of sensitive therapeutics (39-44). MAA is readily 
polymerized and has a pKa that aligns with the natural pH transition in the GI tract, such 
that systems remain collapsed in acidic pH (i.e. gastric conditions) and swell in the 
neutral environment of the upper small intestine for targeted release. 
Based on the characteristics of these systems, the main goal of this research was 
to develop a composite platform as an oral vaccine strategy. The microencapsulation of 
polyanhydride nanoparticles could enable protection through the harsh environment of 
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the GI tract and target delivery proximal to the antigen sampling cells within the small 
intestine. These nanoparticles, in turn, possess “pathogen-mimicking” characteristics and 
sustain antigen release that facilitates cellular uptake, antigen presentation, and immune 
stimulation. Herein, the development of microencapsulated polyanhydride nanoparticles 
as a strategy for subunit oral vaccine delivery is evaluated. The evaluation of these 
composite microparticles is presented, including characterization of polymer 
composition, behavior, and ability to release model protein antigen (Chapter 4); safety 
and immunostimulatory behavior in in vitro models (Chapter 5); and ability to induce 
systemic and mucosal antibody protection in vivo (Chapter 6).  
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Chapter 2: Background2
,3 
 
2. 1 INTRODUCTION 
Development of vaccines administered orally is desirable for numerous reasons 
including improved safety and compliance, and easier manufacturing and administration. 
Additionally, the oral route enables stimulation of humoral and cellular immune 
responses at both systemic and mucosal sites to establish broader and long-lasting 
protection. However, oral delivery is challenging, requiring formulations to overcome the 
harsh gastrointestinal (GI) environment and avoid tolerance induction to achieve effective 
protection.  
This chapter presents a systematic analysis of the barriers associated with the 
gastrointestinal delivery of vaccines and design strategies for novel delivery vehicles and 
next-generation oral vaccine development. Section 2.2 discusses the motivation to 
develop effective strategies for subunit vaccine delivery, and the physiological and 
immunological criteria to inform vaccine design. Section 2.3 reviews particle systems 
designed for oral administration of subunit vaccines. Section 2.4 discusses the advantages 
of the materials used in this work, specifically responsive hydrogels for oral delivery 
applications and polyanhydride materials for drug and vaccine delivery.  
                                                 
2 L. Sharpe, A. Daily, S. Horava, and N.A. Peppas. Therapeutic Applications of Hydrogels in Oral Drug 
Delivery. Expert Opin. Drug Deliv. 2014; 11(6):901-915J. Sharpe was the primary author, while Daily and 
Horava contributed  sections (not included in this background chapter) and Peppas  oversaw the project.  
3 J. Vela Ramirez, L. Sharpe, and N.A. Peppas. Current State and Challenges in Developing Oral 
Vaccines. Adv. Drug Deliv. Rev. 2017, In Press. Vela Ramirez and Sharpe contributed equally to the 
review article and Peppas oversaw the project.  
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2.2 ORAL VACCINES 
 2.2.1 Types of Vaccines 
The history of vaccine development has largely followed Pasteur’s guiding 
principles of “isolate, inactivate, and inject” the causative microorganism, with the 
earliest successes resulting from trial and error (1). However, advances in genetic 
engineering have enabled improvements in the design of vaccine technology and 
diversification of formulation types, thus expanding the number of diseases that can be 
prevented. 
 The earliest vaccines were live attenuated, meaning they contained a version of 
the living microbe that had been weakened or altered in the lab so as not to cause severe 
infection. Live-attenuated formulations most closely mimic natural infections, eliciting 
strong cellular and antibody responses that are likely to confer long-lived protective 
immunity (2).  Unfortunately, live, weakened vaccines can also pose risks such as 
inflammation, uncontrolled replication, and disease, particularly in immuno-
compromised patients. Additionally, though extremely rare, attenuated pathogens have 
the potential to revert to a pathogenic form and cause the disease. For example, the live 
oral poliovirus vaccine (OPV) has not be administered in the United States since 2000 
due to the risk of vaccine-associate paralytic poliomyelitis and the availability of a safer 
alternative in the form of an injected inactivated vaccine (3). Advancements in genetic 
engineering have reduced the unpredictability of experimental attenuation and improved 
the safety associated with live attenuated viruses in a variety of ways, including 
manipulation or elimination of genes required for replication (4). 
A safer alternative to live-attenuated vaccines is killed whole-cell vaccines, which 
consist of the disease-causing microbe inactivated by chemicals, heat, or radiation. 
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Inactivated vaccines can still prompt an immune response, but cannot replicate. 
Consequently, these vaccines are safer and more stable options than live vaccines, but 
stimulate a weaker immune response, generally requiring additional doses or booster 
shots to maintain protection (5, 6).  
While vaccine development has traditionally focused on either live or killed 
whole organism vaccines, next-generation vaccine development has begun to focus on 
even safer and more cost-effective vaccine candidates: subunit vaccines. Subunit 
vaccines are considered the safest alternative as they do not contain any live components 
of the pathogen. They can be divided into four main categories: protein-based, 
polysaccharides, conjugates, and toxoids.  
Protein-based subunit vaccines use a specific and isolated protein that is presented 
as an antigen to the immune system. These molecules can be harvested and purified from 
the cultured microbe or manufactured using recombinant DNA technology(7). However, 
proteins are fragile structures and are easily denatured and degraded by changes in pH or 
presence of proteolytic enzymes(8, 9). Polysaccharide vaccines mimic the polysaccharide 
capsules associated with infectious bacteria, thereby eliciting an immune response. 
Similar to protein subunit vaccines, they are not very immunogenic, and, therefore, are 
associated with short-term immunological responses, not long-term memory.  
Conjugate vaccines also create a response against the pathogen’s protective 
polysaccharide capsule; however, they include a carrier protein in addition to the 
polysaccharides to improve generation of long-term protective immunity. Some of the 
commonly used protein carriers include diphtheria and tetanus toxoids and are, therefore, 
generally used against bacterial infections. Lastly, toxoid vaccines are used against 
pathogens in which bacterial toxin is the primary cause of illness, such as diphtheria and 
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tetanus (7). They are inactivated versions of the toxins and, therefore, are both safe and 
stable. However, most toxoid vaccines require the use of adjuvant, such as aluminum or 
calcium salts, for an effective immune response.  
All subunit vaccines differ from inactivated immunizations by containing select 
antigenic parts of a pathogen that are required to elicit a protective immune response. 
These formulations provide excellent stability and safety profiles, but the process to find 
the appropriate combination of the aforementioned antigenic components in order to 
produce an effective immune response is extremely time-consuming(2, 10). Furthermore, 
subunit vaccines tend to be less immunogenic than their whole-cell counterparts. Current 
research has focused on the addition of adjuvants in order to enhance the immune 
response through inclusion of immunostimulatory molecules or design of antigen-
delivery systems (2).  
2.2.2 Oral Administration 
Oral delivery is the most desirable and patient-accepted route of administration, 
with over 60% of commercialized small molecule drug products using the oral route (11, 
12). Despite this, only a small fraction of currently licensed vaccines are oral 
formulations due to the inherent obstacles presented by the gastrointestinal system. The 
induction of a robust protective immune response by oral immunization requires: (i) 
successful delivery of the intact and active antigen to the intestine, (ii) transport across 
the mucosal barrier, and (iii) subsequent activation of antigen-presenting cells (11, 13, 
14). However, the GI tract poses difficulties to each step, including degradation of fragile 
antigens through the harsh environment in the stomach and requirement of higher doses 
to generate immunity instead of tolerance (15, 16). Each challenge within the GI tract 
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poses a unique engineering problem that requires careful consideration to achieve 
efficacious vaccine design.  
2.2.2.1 Advantages of Oral Administration 
Vaccine efficacy is dependent on both the degree of protection conferred to 
individuals as well as the total coverage, accessibility, and costs associated with 
administering the formulation (17). Vaccine distribution represents one of the main 
limiting factors in the impact of these prophylactic systems, particularly in developing 
nations with limited resources (18, 19). Oral formulations allow for self-administration, 
which is ideal for the widespread and rapid distribution of vaccines as it minimizes the 
need for trained healthcare personnel (20-22).  This could further reduce cost of vaccine 
programs, since training and mobilization of health care workers can account for up to 
25% of the cost of introducing a new vaccine (23). Additionally, needle-free 
administration would eliminate occupational needle-stick injuries, which occur in 
approximately 5% of health-care workers each year, exposing them to blood-borne 
infectious diseases such as HIV/AIDS and Hepatitis (24).  
From a regulation standpoint, oral vaccines could enable more cost-effective 
production since they do not require the extensive purification necessary for injected 
formulations. Parenteral injections require a) aseptic technique during synthesis and 
manufacturing, b) equipment and training of the healthcare personnel for optimal 
delivery, and c) appropriate use of sterile needles (25). Moreover, use of these traditional 
techniques generates a huge amount of biohazardous waste (26), which the majority of 
developing countries simply do not have the infrastructure to handle properly. All of 
these factors increase the cost of immunizations, which can significantly affect their 
access in emergent regions.  
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Oral immunization has the potential to improve vaccine efficacy simply by 
increasing accessibility and coverage, however the oral route also provides the additional 
advantage of stimulating mucosal immunity. The mucosal epithelium covers the largest 
surface area in the body and constitutes the first line of defense against external 
pathogens (16, 27, 28). These mucosal surfaces involve physicochemical and biological 
barriers working in unison to regulate entrance of nutrients and mount responses to 
foreign materials (29-31). Eliciting prophylactic immunity in the infection entry site can 
help prevent infectious diseases. However, the same defense mechanisms designed to 
exclude pathogens must also be circumvented to develop efficacious oral vaccines.  
2.2.2.2 Challenges of Oral Administration 
In order to prompt a robust immune response, the oral delivery of antigens needs 
to overcome multiple physicochemical and biological barriers in the GI tract. Among 
them is the biological barrier of the intestinal epithelium and its mucus secreting layers 
which serve to digest consumed material for nutrient absorption and to protect the body 
from the invasion of pathogenic threats (30, 31). To accomplish these tasks, the GI tract 
includes a highly acidic environment in the stomach, a significant pH range along the 
length of the GI tract, and the presence of proteolytic enzymes responsible for protein 
degradation. These characteristics can interfere with the delivery of fragile biomolecules, 
such as antigenic proteins or peptides, which are highly susceptible to degradation and 
denaturation (11). Furthermore, there is a temporal limitation for the absorption of these 
formulations due to the residence time in the small intestine (3-4 h), where the majority 
of absorption processes occur (32).  
Another major hurdle in the development of oral vaccines is that a higher dose of 
antigen is needed to induce an immune response when compared to traditional parenteral 
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immunizations (16). This characteristic limits the possible formulations used as carriers 
as they must be able to successfully carry the required antigen dosage. Larger doses also 
increase the risk of inducing tolerance instead of stimulating a protective response (20, 
33, 34). The GI tract is constantly exposed to a variety of pathogens. If a vaccine does not 
induce the appropriate danger signals, the body can recognize it as non-pathogenic and 
avoid triggering an immune response, resulting in immune tolerance instead of protection 
(35, 36). Thus, it is critical in the design of oral vaccine carriers to include potent 
adjuvants in order to sufficiently stimulate the immune system. 
2.2.3 The Oral Route: Physiology and Immunology  
The gastrointestinal tract is designed for the digestion and uptake of water, 
nutrients, and small molecules, however, it also performs preemptive and surveillance 
activities to protect the integrity of the system (11, 37). Thus, upon oral administration, 
vaccine formulations encounter a variety of biological and physicochemical mechanisms 
designed to prevent the entrance of foreign material to the body and mount immune 
responses towards them, if necessary. In order to develop next-generation vaccines that 
can overcome the aforementioned challenges in the generation of immunity (and 
avoidance of tolerance) pertinent to the oral route, it is necessary to consider the 
conditions within the gastrointestinal tract.  
2.2.3.1 Organization of the GI Tract 
The GI tract is approximately 20 feet long and it consists of heterogeneous 
surfaces, mucosal thicknesses, pH levels, enzymatic conditions, residence times and 
cellular components (8, 11, 29, 38). As shown in Figure 2.1, the GI tract is divided in 
two broad segments: The upper GI tract includes the oral cavity, pharynx, esophagus, and 
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the stomach; while the lower GI tract involves the small intestine (with three sections: 
duodenum, jejunum, and ileum), the large intestine (also with three divisions: cecum, 
colon, and rectum), and anus (11). Each one of these segments has different purposes and 
carries specific processes designed to absorb nutrients using either passive or active 
mechanisms.  
 
 
 
Figure 2.1 Physiology of the gastrointestinal system and the challenges it presents for oral 
vaccines. 
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Figure 2.2 Anatomy of the gastrointestinal immune system. 
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The surface of the GI tract consists of a physical and chemical barrier formed by 
an impermeable layer of epithelial cells. This barrier functionality is critical as the GI 
tract is the initial point of contact between the body and the external environment and its 
first line of defense against pathogens (31, 39). The lining of the GI tract is composed of 
a heterogeneous population of cells with diverse roles based upon their location (39, 40). 
An overview of this organization is presented in Figure 2.2.  
The most populous cells in the GI tract are the enterocytes, which provide the 
primary barrier functionality of the intestine due to the formation of tight junctions 
between the cells. Additional intestinal cells include goblet cells, Paneth cells, microfold 
or M cells, intestinal epithelial stem cells (IESCs), and enteroendocrine cells (11, 30, 39).  
In order to understand and select appropriate cellular targets for vaccine delivery a 
brief overview of their characteristics is presented in Table 2.1. Based on their cellular 
functions, enterocytes, goblet cells, and M cells are some of the key players involved in 
gut protection, transport, and immunity (36, 41). Specifically, M cells have become one 
of the targets for delivery vehicles to bypass the barriers from the GI system more 
efficiently, and trigger immune responses towards their antigens (42-45). 
In addition to the cellular organization, there is also a critical difference in the 
subjacent layers that constitute the physicochemical barrier of the GI tract. There are four 
layers that form this barrier: mucosa, submucosa, muscularis externa, and serosa (or 
adventitia) (23, 48). Each one of them has different characteristics and cellular 
composition depending on their corresponding roles, as described next. 
a) Mucosa: This is the surface layer of the GI tract and also responsible for 
mucus secretion. It is divided into three different sections: the epithelium, lamina propria, 
and muscularis mucosa. It is the primary point for absorption of food and drug molecules, 
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therefore its cells secrete enzymes (e.g. pepsinogen) and chemical substances (e.g. 
hydrochloric acid) to process nutrients.  
b) Submucosa: This region is where the circulatory, nervous and lymphatic 
systems interact with the gut tissues, specifically with the outer layers.  
c) Muscularis externa: This is an important muscular region, comprised by 
longitudinal and circular fibers that guide the food bolus through the GI tract.  
d) Serosa: The outermost layer of the intestine and consists of multiple 
epithelial sections   
Besides this layered organization of the epithelia, there are also regional 
differences on the thickness and mucosal activity (48). The characteristics of mucus and 
other physicochemical barriers of the GI tract also need to be taken into account when 
developing novel vaccine delivery vehicles to efficiently deliver across them into 
immune cells (38, 48).  
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Table 2.1 Characteristics and functions of intestinal cells. 
Cell type Characteristics Function References 
Enterocytes 
-Most abundant cells in the 
small intestine 
-Column-like shape 
-Have an apical membrane 
domain covered by microvilli 
and a carbohydrate glycocalyx 
-Nutrient digestion and absorption 
-Ion uptake from lumen to 
enterocyte cytoplasm 
-Important for innate immunity 
(8, 30, 39, 
46) 
Goblet cells 
-Mucus-secreting (especially 
MUC 2) 
 
-Maintenance of the mucus 
protective layer 
-Regulation of intestinal wall 
(8, 30, 47-
49) 
Paneth cells 
-Located in the deepest parts 
of the crypts of Lieberkühn 
(formed by the folding of the 
intestine) 
-Shielding the epithelial wall by 
generation of antimicrobial 
proteins (AMPs) that disrupt 
pathogen integrity 
(39, 50-52) 
M cells 
- <1% of total cells in the 
intestinal lumen 
-Cover lymphatic bodies, 
including lymphoid follicles 
and Peyer’s patches 
-Short microvilli and thin 
mucus layer 
-Heavily invaginated 
-Have a protruding glycocalyx 
-Efficient transcytosis activity 
-Antigen sampling 
-Actively transportation of 
pathogens 
-Receptor-mediated and non-
specific antigen uptake 
-Delivery of these microbial parts 
to sub epithelial dendritic cells 
(16, 37, 39, 
45, 49, 53) 
Intestinal 
epithelial stem 
cells (IESCs) 
-Located at the base of the 
crypts in the colon 
-Continuously migrate and 
mature to their final shedding 
into the lumen 
-Maintenance of healthy cellular 
populations in the intestine 
(50, 54, 55) 
Enteroendocrine 
cells 
-Located in the mucosa 
-Placed between other 
epithelial cells 
-Secretion of hormones important 
for digestive functions 
-Mediation interactions between 
central and enteric endocrine 
systems 
(30, 56) 
 
2.2.3.2 Biological and Physicochemical Barriers 
Epithelial cells form the physical and biological barrier that prevents the 
permeation of pathogenic material into the human body, though there are also additional 
physicochemical barriers involved in the mucosae (64). One of the most critical barriers 
is the presence of a robust mucus lining. Mucus is a hydrogel (>95% water) consisting of 
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a mixture of proteins, carbohydrates, lipids, salts, and antibodies (38, 54, 55). This 
complex fluid is primarily generated by mucins secreted by goblet cells. There are over 
twenty different mucin molecules in this family, of which the most abundant are MUC2, 
MUC5AC, and MUC6 (38). These mucin molecules act as monomers, which are 
subsequently linked by disulfide bonds to synthesize larger molecules that can reach sizes 
of 0.5-40 MDa (38, 64).  The resulting mucus lining is a tridimensional crosslinked 
network of the aforementioned mucins (2-5% w/w), which forms a viscoelastic gel with 
shear-reducing properties that can vary depending on the composition, site, and 
physiological conditions (38, 55).  
The lubricating and shielding functions of mucus are essential in maintaining a 
healthy homeostasis (65). The mucus lining contains both a firmly and a loosely adherent 
layer, the thicknesses of which are dependent upon their location along the GI tract. The 
presence of both the firmly and loosely adherent layers creates a slippage plane, which 
aids in the transport of undigested food and is essential for the protection and integrity of 
the GI tract (38, 64). Firm layers are formed by cell-bound mucins, glycolipids and 
glycoproteins that constitute the glycocalyx (38, 54). There are five mucins that are 
known to be present in the GI tract, MUC1, MUC3, MUC4, MUC12, and MUC13 (37). 
The thickness and composition of the loose layers have shown to be dependent on the 
diet of the subject (66). Since this mucus layer is focused on coating and lubricating 
undigested material, it protects the firmly bound layer through the peristaltic motion in 
the GI tract (55, 64). This structural composition is one of the reasons that mucus has 
such an important role maintaining the integrity of the GI system. Penetration of the 
mucus layer is one of the most important characteristics that orally administered vaccines 
need to have in order to reach the immunological sites within the gut. 
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One of the most formidable challenges that vaccine delivery vehicles need to 
overcome, specifically for protein antigens, is the composition of the gastrointestinal 
fluid (39, 67). This complex mixture is composed of water, bile salts, and enzymes (e.g. 
pepsin) and its hydrogen ion concentration changes its overall pH depending on its 
location (39, 68). Enzymatic degradation, in particular, poses one of the most significant 
threats to the stability of protein molecules delivered orally (39, 45). These enzymes are 
multiple proteases such as pepsin, trypsin, and lipase.  
Pepsin, which is present in the stomach, is a proteinase that hydrolyses protein 
amide bonds. The activity of this enzyme is enhanced under acidic pH (<2.5), and it loses 
its activity at pH higher than 8 (50, 69). This characteristic allows it to perform digestive 
functions at the low pH environment in the stomach. Another enzymatic protein present 
in the GI tract is trypsin. This protease is secreted by the pancreas and, together with 
carboxypeptidase and chymotrypsin, is present in the duodenum in large quantities (>1 
g). The action of these three enzymes is responsible for 20% of the degradation of 
ingested proteins (50, 70). The remaining degradation is completed by the actions of the 
aforementioned elements of the gastrointestinal fluid.  
Another physicochemical barrier that has a very critical role in is the variation of 
pH throughout the GI tract. Most proteins are sensitive to their pH environment, with 
their stability at risk in acidic conditions due to the possible denaturation of their 
structure. The GI fluid is made of a mixture of saliva, ingested food and liquid, and 
refluxed liquid from the intestine, therefore the pH of each intestinal segment varies 
depending on the location, and the fasted or fed state of the host (23). 
 Overall, the pH range of the GI system varies from 1.0-7.0; in the stomach it is 
between 1.0-3.0, in the duodenum it fluctuates between 6.0 and 6.5; and in the colon it is 
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5.5-7.0. This gradient in pH is due to changes in the overall concentration of hydrogen 
ions caused by the presence of hydrochloric acid (HCl). In addition to affecting the 
stability and activity of delivered biomolecules, the pH directly impacts the dissolution of 
drugs and proteins (71).  It has been shown that the pH of the stomach is between 1.0-2.0 
(with 0.01-0.1 M HCl) in the fasted state, and ranges from 3.0-7.0 (10-3-10-7 M HCl) 
after food ingestion (39). The significant changes in the local pH of the GI tract have a 
measurable impact on orally delivered proteins and necessitates specially designed 
antigen delivery carriers to accomplish oral vaccination (39, 68). 
2.2.3.3. Gastrointestinal Immunity 
The ultimate challenge of any antigenic administration is the elicitation of a 
robust response towards the immunogen. As previously discussed, there are multiple 
biological and physicochemical barriers that oral vaccine formulations have to overcome. 
However, if they succeed, they still need to stimulate the immune system by engaging 
their activation mechanisms. The intestine is the mucosal site that holds the highest 
number of immune cells in the body, and it is regulated by the gut-associated lymphoid 
tissue (GALT), that coordinates effector and inductive sites (21). Inductive sites in the GI 
tract involve the coordinated action of Peyer’s patches, lymphoid follicles and antigen 
presenting cells (APCs), while effector sites mainly include the lamina propria (LP) and 
surface epithelium.  
Following administration of oral vaccines, antigens travel through the GI tract. 
Upon entering the small intestine, M cells in the Peyer’s patches sample and transport the 
immunogens across to APCs. These materials are then taken up and processed by DCs 
that present antigenic fragments on their surface to activate naïve CD4+ T cells (56). 
These helper cells further interact with antigen-specific B cells that then undergo class 
  
25 
switching to become immunoglobulin-secreting cells. Upon maturation, B cells travel 
from the Peyer’s Patches through the lymphatic system to reach the mesenteric lymph 
node before entering systemic circulation. When these cells reach distant effector sites, 
they differentiate and maturate into plasma cells. In parallel, dendritic cells (DCs) migrate 
to the lymph nodes to activate humoral and cellular responses by interacting with 
germinal centers. A further analysis of the characteristics of the most relevant immune 
sites in the GALT is necessary to understand the process of generating gut immunity 
(21). 
Peyer’s patches (PP) are believed to be one of the largest lymphoid tissues in the 
GALT. They are formed by organized immune cells, and generally include B-cell rich 
follicles protected by a mesh-like formation known as the interfollicular region (IFR) 
made by T-cells (43). They are slightly elevated lymphatic organs with a dome shaped 
structure that are located in the ileum within the small intestine. PPs have only efferent 
lymphatics; therefore they are protected by a follicle-associated epithelium (FAE). This 
FAE contains the previously described M cells that allow the sampling and transport of 
antigenic fragments from the intestinal lumen into the PPs (48). These formations 
represent the main port of entry for antigens in order to elicit immunity in the gut and 
mucosae. Active targeting mechanisms towards M cells are being explored in order to 
efficiently deliver antigen into the Peyer’s patches (21, 43). Further exploration of these 
strategies is discussed in detail in a subsequent section.  
Some of the most common and important APCs present in the GALT are DCs. 
They take advantage of their location in the sub epithelial dome (SED) region below the 
FAE, where they can take up antigens directly from M cells (43, 56, 72). DCs are 
specialized immune cells that process and present antigenic fragments to mucosal B and 
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T cells to initiate antigen-specific immunity. There are three different DC subsets present 
in the GI tract: CD11c+ DCs in the SEDs, CD8α+ DCs in the IFRs, and CD11c-CD8α- 
DCs in both locations (73). Finally, these cells play a significant role in the homing of 
activated T and B cells to the lamina propria, because of their processing ability of 
retinoic acid (43). They express retinal dehydrogenase, an enzyme that can transform 
ingested vitamin A into retinoic acid (74). This molecule induces gut imprinting 
molecules including α4β7 integrin and CCR9 (75). Engagement of these APCs is critical 
in the initiation of local and systemic immunity; hence development of vaccine delivery 
carriers with targeting mechanisms towards these cell populations is important.  
As previously mentioned, recruitment and activation of B and T cells are 
important in the generation of adaptive and long-lasting immunity towards an antigen. B 
cells make up the 75% of the cellular population of PPs, and are primarily located in the 
follicle region (43). It is in these locations that germinal centers form, including during 
homeostatic conditions (43). Germinal center formation is characteristic of strong 
thymus-dependent antibody responses, and the generation of GC B cells is an important 
part of triggering T helper cell responses (76). These antibody-secreting lymphocytes are 
critical in the generation of serum and mucosal immunoglobulins and the host protection 
from bacterial and viral infections.  
Cellular responses, generally performed by T cells, represent the other 
fundamental component of immunity. These populations are also involved in the 
development of robust humoral responses, via the initiation of B cell maturation. 
Follicular helper CD4+ T cells (TFH) provide essential co-stimulatory signals to B cells 
in germinal centers (29, 43, 77). Naïve T cells in the GALT are located mainly in the PPs, 
where they represent 20% of the total cell population (43). However, there are also other 
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phenotypes (e.g. Th1, Th2 and Treg) present in the gut (78, 79). Upon their activation, 
they can become tissue-resident memory T cells, or circulating-memory T cells, both of 
which may be more effective defense mechanisms than antibody-based responses. 
Memory cells control an infection by the secretion of cytokines and recruitment of other 
immune cells (77). However, they can also cause tissue damage if there is a prolonged 
infiltration of such cell populations.  
The barriers and challenges for antigen delivery in the GALT discussed in this 
section underline the need of novel design mechanisms for antigen delivery that can 
protect the cargo, penetrate the biological and physicochemical barriers, and possess 
adjuvant capabilities that can elicit robust and balanced immune responses. Optimal 
vaccination strategies would generate both humoral and cellular immunity with innate 
and adaptive components.  
2.3 ORAL VACCINE STRATEGIES: DELIVERY SYSTEMS  
As previously mentioned, subunit vaccines require the use of delivery systems 
and/or immunostimulants to induce immune protection. In order to efficiently deliver 
stable antigens, it is necessary to: i) design carriers that can protect the payload through 
these conditions (57), ii) release the vaccine within the small intestine residence time to 
antigen presenting cells across the epithelial layers, and iii) enhance the immune 
responses elicited by the vaccine with the adjuvant capabilities of the delivery vehicles 
(19).  
There are a multitude of parameters to be taken into account when designing 
delivery systems for the oral delivery of subunit vaccines. Among some of their 
controllable properties include size, geometry, antigen loading and release kinetic 
capabilities, and finally the ability to include functional molecules to improve their 
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performance. Tailoring these characteristics can prolong the residence time of 
immunogens, enable the co-delivery of antigens and adjuvants to boost their 
immunogenicity and target immune cells (specifically APCs) for efficient transport, 
uptake and presentation. Furthermore, the material properties of these vehicles have the 
potential to act as immune-potentiators as well.  
This section includes a brief overview of the most commonly explored delivery 
vehicles for oral vaccination, as shown in Figure 2.3, their characteristics, and the 
responses obtained after their administration.  
 
 
Figure 2.3 Polymeric and particulate oral vaccine delivery vehicles  
 
2.3.1 Polymeric/Particulate Vaccine Design 
Polymeric microparticles (MPs) and nanoparticles (NPs) have been extensively 
explored for the development of subunit-based vaccines. Proteins, DNA, and 
polysaccharide vaccine components are fragile molecules that could be structurally 
degraded during transition through the gastrointestinal tract or the mucosal layer, 
resulting in diminished bioactivity. Entrapment or encapsulation of the antigenic payload 
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within polymeric particles affords protection, while also preventing antigen dilution over 
the large surface area of the GI tract. In addition to robust structural stability, particles 
can provide control over release site and profile for improved delivery of stable antigens. 
Furthermore, NP carriers have demonstrated the capability to efficiently deliver an 
antigenic payload directly to phagocytic APCs through passive or active targeting to 
stimulate cellular and humoral responses(58).  
Particulate delivery systems passively provide characteristics of adjuvant behavior 
to weakly immunogenic subunit vaccines simply by virtue of APC recognition and 
internalization. However, NPs enable the incorporation of enhanced adjuvant strategies 
through co-delivery of immunomodulators or by manipulation of surface properties for 
enhanced or targeted uptake by immune cells, a strategy that is further discussed in 
section 7 (59). Furthermore, there is a diversity of both synthetic and natural materials 
with desirable physicochemical properties capable of responding to physiological 
changes, making polymeric particles a versatile option for rational vaccine design (60).  
2.3.1.1. Synthetic Polymers 
Polyester nanoparticles, in particular poly(lactic) acid (PLA) and poly(lactic-co-
glycolic) acid (PLGA), are the leading synthetic polymers explored in preclinical studies 
for oral vaccine administration due to their biocompatibility, biodegradability, and 
controlled sustained release patterns of encapsulated antigens for up to several 
months(61-63). Additionally, both PLA and PLGA are FDA-approved materials, which 
can expedite the development and approval of the delivery carriers.  
Biodegradable vaccine delivery systems allow for prolonged antigen release and 
are a viable strategy to achieve single-dose administration, which is particularly desirable 
in the context of reducing number of repeated administrations required for long-term 
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protection and the cost implications for mass vaccination campaigns. For several antigens 
studied, including plasmid DNA and protein antigen payloads, single administration 
significantly improved long-term IgA and IgG antibody titers in comparison to soluble 
antigen, attributed to sustained antigen release mediated by particles (64-67).  
Antibody responses can be further improved compared to encapsulation of the 
antigen alone by co-delivery of antigens with immunostimulants, such as the TLR4-
adjuvant monophosphoryl lipid a (MPLA) (68), or co-polymerization with PEG as a 
stabilizer to improve NP stability in gastrointestinal conditions and antigenicity of 
encapsulated antigen (69). Zhu et al. designed a PLGA-based system containing both 
immunostimulant and GI stabilizing strategies for an effective HIV peptide vaccine. 
PLGA nanoparticles containing three different TLR ligands and the HIV Env epitope 
were coated with the methacrylate-based polymer Eudragit FS30D (70). This pH-
responsive polymer was chosen to selectively deliver the antigenic payload to the large 
intestine. While orally administered PLGA nanoparticles induced local responses in the 
small intestine, the two-part PLGA/Eudragit microparticle formulations induced 
immunity in the rectal and vaginal mucosa, ultimately protecting against rectal or vaginal 
viral challenge. The study demonstrates the possibility to target regions of the GI tract in 
a pH-dependent manner. 
While these polyesters provide several advantages for vaccine design, 
acidification of the microenvironment within the delivery vehicles upon degradation can 
prove to be unfavorable for the encapsulated agents, causing disruption to tertiary 
structure and protein degradation (71, 72). Efforts have been made to optimize PLGA 
particle fabrication methods and add stabilizing agents, which have helped to alleviate 
deleterious effects of local acidification (65). In a strategy to circumvent the stability 
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issues associated with encapsulation, PLGA has been evaluated as an adjuvant for 
particulate delivery of surface-adsorbed antigens (73, 74). This strategy does not afford 
controlled release of the antigen, but could provide an organic and biodegradable 
alternative to inorganic adjuvants such as alum. 
Additionally, other synthetic pH-responsive materials have been explored for oral 
vaccination due to their ability to protect antigens from degradation and provide targeted 
release. Mannan-coated methacrylic acid-based copolymers demonstrated both pH-
dependent release of encapsulated antigens as well as uptake and activation of APCs (75), 
while co-delivery of antigen with the mucosal adjuvant cholera toxin (CT) elicited 
significantly increased IgG and IgA antibodies as compared to soluble dosages(76).  
2.3.1.2 Natural polymers 
Natural polymers (e.g. polysaccharides) tend to be non-toxic, biocompatible, and 
biodegradable as well as possess mild gelation conditions for encapsulation of sensitive 
macromolecules. They have been extensively explored in drug delivery applications. 
Additionally, carbohydrates are desirable oral vaccine components given the numerous 
lectin-receptors expressed by M cells in the intestinal mucosa.  
Chitosan is a cationic polysaccharide with advantageous properties for oral 
delivery including mucoadhesion and an ability to reversibly disrupt epithelial tight 
junctions(77, 78). However, chitosan particles are limited by their high solubility in 
acidic conditions, risking the integrity of the sensitive payload. Strategies to overcome 
chitosan’s dissolution in acidic pH include encapsulation of antigen-loaded chitosan 
particles within liposomes to protect transit through the stomach (79), stabilization by 
crosslinking with tripolyphosphate and glutaraldehyde (80), and electrostatic coating with 
the anionic polysaccharide alginate (81, 82). These strategies significantly improve 
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particle stability and payload retention in acidic environment to protect the antigen, and 
induced significantly higher antibody titers in vivo as compared to unmodified chitosan 
particles.  
2.3.2 Lipid-based Vehicles  
Lipid-based vaccine delivery carriers are some of the most commonly used 
vehicles for oral administration. Among these are liposomes, bilosomes, and immune-
stimulating complexes (ISCOMs). They are based on the separate encapsulation of 
hydrophilic and lipophilic agents using lipid bilayers. 
2.3.2.1 Liposomes 
Liposomes are spherical vesicles formed by one or more phospholipid bilayers 
synthesized from cholesterol and other non-toxic lipids. The properties of these systems 
vary depending on their composition (i.e. their size, charge, and protein compatibility), 
and can be optimized by changing their fabrication parameters. These liposomal systems 
also offer the ability to deliver multiple active agents with vastly different properties, 
since they can be located in different compartments of the carrier. Specifically, water-
soluble molecules, such as proteins, RNA, carbohydrates, or peptides are encapsulated in 
the inner layer of these vehicles; meanwhile lipophilic compounds can be included in the 
external section of the formulation (83, 84). 
A variety of liposome-based vaccines for oral administration have been 
previously synthesized to target a wide range of viral and bacterial diseases. For example, 
an influenza A viral vaccine was produced using a construct DNA vaccine with a pcDNA 
3.1(+) plasmid encapsulated in cationic liposomes. Oral immunization with this 
formulation induced humoral and cellular immune responses, in addition to increasing 
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cytokine production (85). Liposomes have also been used to prevent bacterial infections, 
such as Salmonella Enteritidis. A vaccine to prevent this disease was created using a 
liposome-associated carrier with the recombinant SefA protein by Pang and 
collaborators. This oral vaccine was able to generate protective immunity in chickens and 
a significant reduction of intestinal bacterial load was observed after oral challenge with 
2 x 10
6
 CFUs of live Salmonella Enteriditis (86). 
Liposomes have demonstrated their ability to deliver diverse antigens, including 
DNA, peptides, and proteins. For example, encapsulation of a DNA-based antigen 
(Mycobacterium pcDNA3.1
+
/Ag85A) in liposomal formulations enhanced its presence in 
the epithelium, M cells, DCs and PPs within the small intestine of C57BL/6 mice after 
three oral immunizations. The ability of the system to induce antigen-specific mucosal 
immunity made this formulation a potential vaccine carrier (87). In a different study, 
delivery of antigenic peptides and CTL epitopes within liposomes allowed their 
efficacious transport to APCs and improved the host response towards these antigens (88-
90). Additionally, the adjuvant capabilities of these formulations have been tested using 
model antigens (e.g. ovalbumin, bovine serum albumin). These experiments have shown 
that liposomes can effectively load and release stable protein. They are also able to elicit 
Th1/Th2 immunity, reflected by the generation of mucosal and systemic antibody 
responses(15, 83, 91, 92). Finally, these systems can also be decorated with targeting 
molecules (e.g. carbohydrates) to enhance their efficacy. In oral immunization 
experiments, lectinized liposomes were able to effectively target M cells in the PPs, 
resulting in elicited mucosal responses with high antibody titers (83, 93). Overall, 
liposomes have shown promising properties for vaccine delivery applications.  
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2.3.2.12. Bilosomes 
A different lipid-based carrier being explored for oral immunization is bilosomes. 
These non-ionic surfactant vesicles have adjuvant functionalities and incorporate bile 
salts in their formulation. Bilosomes are typically synthesized with monopalmitoyl 
glycerol (MPG), cholesterol (CH), and dicetyl phosphate (DCP); and surfactants such as 
sodium deoxycholate (SDC), or sorbitan tristearate (STS).  Similar to liposomes, 
bilosomes also have a bilayer with polar and non-polar ends, permitting the integration of 
vaccine elements with significantly different properties.  
Traditional liposomal vesicles can be disrupted by bile salts; however, if vesicles 
are fabricated in the presence of bile salts, such as bilosomes, they are no longer affected 
by their action and remain stable. These systems are able to stimulate humoral and 
cellular immune responses and the inclusion of bile salts allow the protection of the cargo 
from the harsh environment from the GI tract (94-96). One of the main advantages of 
bilosomal formulations is the improved stability that they can confer to fragile antigens. 
In previous studies it has been shown that bilosomes are able to entrap and stabilize a 
variety of fragile antigens, including tetanus toxoid (TT), A/Panama (influenza A 
immunogen), diphtheria toxoid, Bac-VP1 (hand, foot and mouth disease vaccine 
candidate) (94, 96-101).  
Additionally, adjuvant and drug release studies with bilosomes have been carried 
using model antigens such as bovine serum albumin (BSA) and cholera toxin subunit B 
(95, 102). Their immunogenic abilities have also been explored using various disease 
models. Previously, mannosylated bilosomes targeting DCs for oral immunization against 
hepatitis B virus generated both systemic and local immunity, including in the mucosa 
(98).  
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The use of these formulations induced production of soluble immunoglobulin A at 
all local and distal sites of the GI tract. A different set of studies performed using a 
subunit vaccine against influenza in an orally administered formulation also elicited high 
antibody titers and cellular responses. Specifically, Th1 and Th2 responses were 
successfully produced(95, 98). As summarized here, the aforementioned benefits 
provided to different antigens because of bilosomal entrapment, make this system a 
feasible vaccine delivery platform for oral immunizations.  
2.3.2.3. Immune-stimulating Complexes  
Immune-stimulating complexes (ISCOMs) are second-generation liposomes 
regarded as both a carrier and as an immunostimulant for vaccine delivery. Synthesized 
using colloidal saponin (often QuilA extracted from the tree Quillaja saponaria), 
cholesterol and other phospholipids (generally phosphatidylethanolamine or 
phosphatidylcholine), these nano-sized vectors (~40 nm) with self-adjuvant abilities are 
organized in open-caged structures (15, 103-105). These vehicles have been used to 
entrap bacterial and viral envelope proteins to prompt vaccines against such pathogens. 
Classical ISCOMs are self-assembling systems fabricated in the presence of a non-ionic 
detergent that is removed post-synthesis (104).  
These formulations have been shown to have a great breadth of applications, 
incorporating antigens to prevent herpes simplex virus 1, hepatitis B, respiratory 
syncytial virus, Escherichia coli, Brucella abortus, and Plasmodium falciparum 
infections (104, 106-108). ISCOM-based vaccines have shown to be highly 
immunogenic, generating balanced humoral and cellular responses in different animal 
models(104). The properties of this system engage components of both the innate and 
adaptive immune systems. This characteristic makes this platform a highly desirable 
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delivery methodology, although their intricate action mechanisms remain to be fully 
elucidated.  
2.3.3 Adenoviral vectors  
Traditional vaccines were based on the use of killed or attenuated pathogens, but 
as previously discussed there are risks in the immunization of vulnerable populations 
with such platforms due to the potential reversal of their pathogenicity. However, with 
advances in genetic engineering and molecular virology, there are some alternatives for 
the use of such microbial structures without their detrimental side effects. Adenoviruses 
are double-stranded DNA viruses, with a ~40 kb genome, they are species-specific and 
have different serotypes. While this platform was initially devised for gene delivery, due 
to its highly immunogenic nature it became less attractive for therapeutic use.  
However, based on the advancement and optimization in the synthesis of 
adenoviral vectors, they have become interesting possibilities as vaccine delivery carriers. 
The adenoviral genome is well studied and can be readily manipulated, thus allowing the 
synthesis of non-pathogenic vectors. Another advantage of these systems is that most of 
these viruses in their original form only induce mild diseases in immunocompetent 
human adults. These systems can also be modified to nullify their replication mechanism, 
further reducing their ability to infect a host.  
The previously mentioned features have prompted the use of adenoviral vectors as 
vaccine delivery vehicles for the treatment of viral diseases. Vaccines using adenoviral 
vectors have targeted a wide range of some of the most challenging diseases, including 
HIV, influenza, rabies, botulism, dengue, SARS and Ebola (109-116). They are able to 
generate robust cellular and humoral immune responses. Oral immunization with the 
most common adenoviral vaccine vectors (AdHu5) have been shown to induce potent 
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CD8+T cell responses and antibody responses, but not engage CD4+T cell responses 
(109, 117-119). The multiple isotypes (e.g. IgG2a, IgG1) generated by such vectors 
indicates the elicitation of a Th1/Th2 response, however it is predominantly skewed 
towards the first one(109).  
Additionally, adenoviral vectors activate innate immunity mechanisms by the 
expression of pathogen-associated molecular patterns (PAMPs) on their surface, initiating 
the secretion of pro-inflammatory cytokines, activation of complement, and the 
differentiation of APCs. One of the important considerations during the development of 
novel delivery vehicles is their ability to induce strong responses in relevant models for 
clinical application. These systems have been used for administration of vaccines in 
multiple animal models including rodents, dogs, non-human primates, and most 
importantly, they have reached human clinical trials (109). By taking advantage of their 
immunogenic characteristics, adenoviral vectors represent an alternative to killed or 
attenuated vaccines, and their further use and optimization remains as a valuable option 
for pathogen-mimicking delivery vehicles.  
 
2.4 BIOMATERIALS FOR COMPOSITE ORAL VACCINE PLATFORM DESIGN  
Employing multiple materials in a composite design can address the distinct 
nature of the challenges associated with i) protecting subunit antigens through the GI 
tract for targeted delivery, and ii) stimulation of immune cells to generate a protective 
response. The development of intelligent hydrogels for oral delivery of sensitive 
therapeutics and polyanhydride materials as nanovaccines with subunit antigens are 
discussed herein to motivate their selection in this work.   
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2.4.1 Hydrogels for oral protein delivery 
Hydrogels are three-dimensional, polymeric networks consisting of crosslinked 
hydrophilic components.  In certain environmental conditions, hydrogels can imbibe 
large amounts of water or biological fluids while remaining insoluble. Physical integrity 
in aqueous media is maintained by physical crosslinks (e.g., entanglements, crystallites) 
and/or chemical crosslinks (e.g., tie-points, junctions) (120-123). High affinity for water 
absorption gives hydrogels physical properties resembling living tissues, such as a soft 
consistency and low interfacial tension with aqueous media. These properties match 
living tissues more than any other class of synthetic biomaterial, and are therefore highly 
biocompatible for biological applications (124). Hydrogel use thus extends beyond the 
drug delivery applications discussed here, to tissue engineering, surface coating, contact 
lenses, and diagnostics among others (124-131). 
 Stimuli-responsive hydrogels are of particular interest for oral delivery as they 
can respond to environmental changes to alter network structure, swelling behavior, 
permeability, or mechanical strength, as well as control drug release (132). Many 
different physical and chemical stimuli have been applied to smart hydrogel systems. 
Physical stimuli include temperature, electric field, and light. Chemical and biochemical 
stimuli, such as pH, ionic strength and molecular recognition events, are more commonly 
exploited in oral delivery (121).   
The primary barriers to oral delivery of therapeutics, particularly protein and 
peptide drugs, as discussed in Section 2.2.3 are (i) inactivation in the gastrointestinal (GI) 
tract due to denaturation by acidic pH or digestive enzymes and (ii) poor permeability 
through the epithelial membrane into the bloodstream (126).  Hydrogels provide a 
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platform to protect therapeutics through the complex environment of the gastrointestinal 
tract and achieve site specific delivery utilizing fundamental physiological changes.  
2.4.1.2  pH-Responsive Hydrogels  
pH-Responsive hydrogels have become popular platforms for the oral delivery of 
drugs. Such systems can be tailored for drug delivery to specific organs (e.g., small 
intestine, colon), or intracellular vesicles (e.g., endosomes, lysosomes).  For intestinal 
delivery, particles on the micron-scale (1-1000 μm) offer a larger surface area and are not 
taken up by M cells (133). Particles on the nanoscale (50-200 nm) are used for intestinal 
delivery for cellular internalization (134, 135). Particles less than 10 nm are cleared by 
lymph drainage (134).  The two basic strategies for imparting pH-responsive behavior are 
incorporating (i) ionizable groups with solubility and/or conformational changes in 
response to environmental pH, and (ii) acid-sensitive bonds that cleave to release 
molecules anchored into the backbone (136). Ionizable polymeric systems are pH-
sensitive due to the basic or acidic pendant groups of the polymer network. Ionization of 
the pendant groups results in a net charge in the polymer network. Due to the electrostatic 
repulsions of the charged polymer network, the pores increase in size, allowing for the 
influx of water and increased swelling.  
pH-Responsive hydrogels can be classified as anionic or cationic. Anionic 
hydrogels are ionized, and thus swollen, at a pH higher than the pKa of the polymer 
network (123, 137). Intestinal drug delivery systems take advantage of pH-responsive 
anionic hydrogels to protect drugs from gastric degradation and denaturation at low pH 
and release drugs in specific locations, such as the upper small intestine and colon, 
further in the GI tract. Ionic strength of the solution also affects the swelling of pH-
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responsive hydrogels (138, 139). At pH below the pKa, there is minimal effect of ionic 
strength on swelling since the hydrogel is in the collapsed state. Experimental 
observations found that as the ionic strength increases, the degree of swelling decreases 
for anionic hydrogels at a pH above the pKa of the polymer network (139, 140). 
Increasing the ionic strength of the solution leads to ion shielding which diminishes the 
degree of electrostatic repulsion of the negative carboxylic acid groups (141).  
In contrast to anionic hydrogels, cationic hydrogels are ionized at a pH lower than 
the pKa of the polymer network (142). Cationic hydrogels are suited for drug release in 
the stomach or intracellular environments. Amino acid groups of cationic polymers 
impart high water solubility at acidic pH and low water solubility at neutral pH. In an oral 
delivery system, cationic polymers provide protection of the drug in the oral cavity (pH 
5.8 - 7.4) (143), while releasing the drug in the stomach (pH 1 - 3.5) (144). Due to the 
low solubility at neutral pH suppressing drug release, cationic polymers often serve as 
taste-masking formulations (144-147).  
Our lab has successfully developed complexation, pH-responsive copolymer 
systems that address the aforementioned barriers with immense potential in oral 
therapeutic delivery. These systems consist of a family of grafted copolymers that include 
poly(ethylene glycol) (PEG) grafted on poly(methacrylic acid) (PMAA), designated as 
P(MAA-g-EG), as well as other polyacids (Figure 2.4).  These complexation pH-
sensitive hydrogels respond to the surrounding environment, protecting drugs from the 
harsh environment of the stomach, and releasing them in the small intestine. Methacrylic 
acid (MAA) imparts pH-sensitivity due to the ionizable carboxyl pendant groups. 
Carboxylic acids begin to deprotonate at pH values above its pKa of 4.8, developing a 
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negative charge in the network. The ratio of deprotonated to protonated carboxylic acid 
groups can be determined using the Henderson-Hasselbach equation  
 
𝑝𝐻 = 𝑝𝐾𝑎 + 𝑙𝑜𝑔
(𝐴−)
(𝐻𝐴)
      (Equation 2.1) 
where pH is the environmental pH, pKa is that of the acid group, (A
-
) is the 
concentration of deprotonated acid groups, and (HA) is the concentration of protonated 
acid groups. Interpolymer complexation occurs when protons of the carboxylic acid 
groups of PMAA backbone form hydrogen bonds with the etheric oxygen of the PEG 
tethers (148).  
 
  
Figure 2.4 Representative structure of one unit of P(MAA-g-EG)  
At low pH, P(MAA-g-EG) networks are collapsed due to complexation. As the 
environmental pH increases above the pKa of 4.8, deprotonation causes disruption of the 
polymer complexes, as well as ionization and electrostatic repulsion of the acid groups of 
the MAA backbone. The polymer network swells and the mesh size, ξ, increases due the 
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effects of deprotonation, as demonstrated in Figure 2.5. The mesh size, or the network 
correlation length, is the end-to-end distance of the polymer chains between junction 
points. The complexed, or collapsed, network has a mesh size of 70 Å, while that of the 
decomplexed, or swollen, network is 210 Å (149).  In the oral delivery route, this 
network is collapsed in the low pH environment of the stomach, providing protection of 
the drugs, and then swells in the increased pH environment of the upper small intestinal 
allowing for drug release.  
 
 
Figure 2.5 Schematic of anionic complexation hydrogels for pH-responsive oral delivery. 
This class of materials can deliver a therapeutic through the harsh 
environment of the stomach, protecting it from denaturation by acidic pH or 
digestive enzymes. Hydrogels swell in the upper small intestine due to 
decomplexation and subsequent water imbibition that swells the network, 
increases mesh size and enables targeted release of the entrapped therapeutic 
in neutral pH conditions.   
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The pH-responsiveness of P(MAA-g-EG) was first investigated by Klier et al. and 
Peppas and Klier further studied this polymer network for applications in oral drug 
delivery systems (150, 151). An evaluation of grafted PEG chain lengths determined that 
PEG chains with a molecular weight of 1000 exhibited the highest degree of 
complexation in low pH conditions (152) . Equimolar amounts of carboxylic acid groups 
of MAA and etheric oxygen molecules of PEG result in the largest amount of 
complexation (153). Adjusting the amount of carboxylic acid groups or other substituent 
groups tailors the hydrogel system for a specific pH value and, therefore, the site of drug 
release. Our laboratory has optimized the pH-dependent swelling behavior of P(MAA-g-
EG) hydrogel systems for release targeted in the upper small intestine. Previous studies 
have demonstrated the successful use of this hydrogel system for the oral delivery of 
proteins, such as insulin (154, 155), calcitonin (156, 157), and interferon alpha (157). 
Representative in vitro release of insulin from P(MAA-g-EG) microparticles can be 
found in Figure 3 (158). 
Another important feature that takes advantage of the pH-responsive behavior of 
the P(MAA-g-EG) system is release of PEG tethers. In the decomplexed state the grafted 
PEG tethers are no longer hydrogen bonding with carboxylic acids of the PMAA 
backbone and act as mucoadhesion promoters on the surface of the polymer network. 
Tethered PEG chains interpenetrate the mucus layer of the small intestine, participating 
in physical entanglement and hydrogen bonding with the polysaccharide components 
(159).  Mucoadhesion increases the residence time of the carrier at the site of absorption, 
which promotes increased bioavailability (160). It is important to note that pH-sensitivity 
is designed for targeted release of drugs in the upper small intestine, as well as triggering 
the PEG tethers to promote mucoadhesion at the target absorption site.  
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2.4.1.2 Biodegradable Hydrogels  
While the predominant strategy for oral delivery employs pH-responsiveness for 
site specific release in the GI tract, other environmental changes, such as enzymatic 
population, have been exploited to achieve site-specific drug delivery. As mentioned 
previously, colon-specific delivery can be desirable for both local and systemic 
therapeutic treatment.  A common strategy to achieve colonic delivery exploits microbial 
enzymes predominantly found in the colon, such as reductive (e.g., azeoreductases) and 
hydrolytic (e.g., glycosidases) enzymes (161). Dextran hydrogels have potential in 
colonic-specific delivery by undergoing degradation by a dextranase, allowing release in 
the presence of the colon’s microbial enzyme. Bronsted, et al. demonstrated the potential 
of dextran hydrogels for oral delivery by successfully releasing the anti-inflammatory 
agent, hydrocortisone (162). Dextran hydrogels continue to be explored for delivery of 
peptide and protein drugs, such the peptide hormone salmon calcitonin (163).  
Incorporation of cleavable crosslinking agents is another strategy to trigger site-
specific degradation. Azoaromatic bonds as crosslinking agents, which can be degraded 
by azeoredutases, also targets colon-specific delivery. By synthesizing hydrogels 
containing both pH-sensitive monomers and azoaromatic crosslinkers, Kopecek, et al. 
created a system that began to swell in the small intestine, making crosslinks accessible 
to azeoreductases by the time the particles reach the colon for protein drug release (164-
166). More recently, Knipe, et al. demonstrated pH-responsive microgels crosslinked 
with a trypsin-degradable peptide linker to achieve intestine targeted release of siRNA 
loaded nanogels for inflammatory bowel diseases (167, 168) .   
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2.4.2. Polyanhydrides for Drug and Vaccine Delivery 
Polyanhydrides are a versatile class of biodegradable materials used in medical 
and pharmaceutical applications. Degradation is imparted by the hydrolytic reactivity of 
the anhydride linkage (Figure 2.6), enabling modification of the backbone structure 
while maintaining biodegradability of the polymer. The degradation kinetics of 
polyanhydrides can be tailored by modifying the length of the main chain, including 
aromatic or glycol functionalities to tailor relative hydrophobicity/hydrophilicity, and 
copolymerizing anhydride monomers in various ratios (169-173). Additionally, anhydride 
bond cleavage is base catalyzed and, therefore, pH-dependent (174, 175).  
Polyanhydrides are prepared by melt condensation (170), in which a dicarboxylic 
acid is refluxed using an excess of acetic anhydride to obtain a mixed anhydride solution. 
High molecular weight polyanhydrides are obtained by removing the acetic anhydrides 
using high temperatures and vacuum. Reaction time, temperature, and the presence of 
catalysts all have an impact on the resulting polymer chain length, purity and 
polydispersity index.  
 
 
Figure 2.6 Basic chemical structure of polyanhydrides 
 The combination of the hydrophobic backbone and hydrolytically labile 
anhydride linkages enables control over hydrolysis rate simply by manipulation of the 
polymer composition. Examples of monomers for polyanhydrides used as biomaterials 
include those containing aliphatic groups such as sebacic acid (SA) and those containing 
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aromatic groups such as 1,3-bis(p-carboxyphenoxy)propane (CPP), 1,6-bis(p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG), which is structurally similar to CPH but contains ethylene glycol groups in 
place of the hexane in the backbone. Inclusion of more hydrophobic anhydrides, such as 
CPH, into polyanhydride copolymers can drastically slow release of the encapsulated 
payload, while inclusion of the more amphiphilic anhydrides, such as CPTEG, can 
accelerate polymer degradation and impart higher burst effect of the payload (171, 176). 
Degradation rates vary from weeks to several months by simple modification of the 
molar ratio of the monomers (172, 177, 178)  
 The ability to tailor degradation kinetics by adjusting the reacting monomers 
makes polyanhydrides highly desirable materials for drug delivery applications. 
Accordingly, polyanhydrides have been used to encapsulate a wide range of drugs, 
ranging from small molecule drugs to delicate protein therapeutics (179-182). The 
polyanhydride-based Gliadel® wafer, composed of a 20:80 ratio of CPP and SA and 
loaded with carmustine is FDA-approved as a post-surgical brain tumor implant (183).  
 More recently, polyanhydrides have been investigated for mucosal vaccine 
design. In addition to improving the stability of encapsulated antigen as compared to 
other biodegradable materials, such as polyesters, polyanhydride materials have been 
shown to modulate immune response without the requirement of supplementary 
adjuvants (184). Copolymers of methyl vinyl ether (PVM) and maleic anhydride 
(designated as P(VM-g-MA)) have demonstrated Th1-adjuvant activity. Upon 
immunization with ovalbumin-loaded and ligand-coated P(VM-g-MA) nanoparticles, a 
balanced IgG1 (Th2) and IgG2 (Th1) response  was generated (185, 186). Th1-adjuvant 
capacity was mediated by nanoparticles promoting a close interaction between the 
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antigen and APCs, which can be further enhanced with targeting strategies, and also by 
acting as an agonist of various TLRs (187). Single dose immunization with P(VM-g-MA) 
NPs containing outer membrane vesicles (OMVs) derived from Shigella induced 
antibody protection (IgG1, IgG2, and IgA) as well as Th1 cytokines, ultimately 
protecting mice against lethal challenge (188), demonstrating the potential of 
polyanhydrides as a platform for protection by subunit antigens.  
Extensive research has been done on polyanhydrides based on various copolymers 
of CPH, SA, and CPTEG (Figure 2.7). These materials have demonstrated 
biocompatibility, antigen stabilization, tailorable release kinetics, and immunomodulatory 
effects in both in vitro and in vivo models (189-195). A diversity of antigenically stable 
proteins have been released after encapsulation into polyanhydride nanoparticles, 
including tetanus toxoid, ovalbumin, PspA (pneumococcal surface protein A), viral 
hemagglutinin (an influenza surface protein), and HIV antigens (172, 176, 196-198). 
Additionally, in vivo studies using murine models have demonstrated the induction of 
humoral and cellular responses after subcutaneous or intranasal administration, sufficient 
to protect against lethal challenge (197, 199).  
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Figure 2.7 Chemical structures of a) sebacic acid, b) 1,6-bis(p-carboxyphenoxy) hexane, 
c) 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane, and d) polyanhydride 
hydrolysis mechanism (172) 
2.5 SUMMARY 
The development of successful oral vaccines using subunit antigens requires 
careful design of delivery vehicles and incorporation of molecules that can potentiate 
their effect to elicit strong and balanced immune responses. As described, there are 
several advantages in the use of the oral route to improve vaccination efficacy; however, 
there are challenges including the protection of these fragile proteins, their release, and 
the adjuvant ability of their carriers.  
There are currently a wide range of materials being explored for design of oral 
vaccine carriers. However, the potential to combine materials that address distinct aspects 
of the challenges to oral vaccination is an interesting strategy. Complexation polymers 
based on methacrylic acid are promising materials for targeted intestinal delivery of 
fragile therapeutics. Polyanhydride nanoparticles have demonstrated desirable 
characteristics for antigen delivery as adjuvants and/or delivery vehicles. Therefore, 
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exploiting the properties of both systems to achieve an oral subunit vaccine platform is a 
promising approach.  
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Chapter 3: Objectives and Specific Aims  
The development of oral subunit-based vaccines requires the use of delivery 
systems to induce immune protection. To elicit protective immunity, these systems must 
i) protect the payload through gastric conditions; ii) deliver stable antigen within the 
small intestine residence time proximal to antigen sampling cells; iii) facilitate transport 
across the epithelial layer to lymphoid tissue; and iv) stimulate antigen presenting cells in 
a pathogen mimicking manner to induce protective immune responses.  
The overall goal of this research was to design a novel composite vaccine delivery 
vehicle to address the challenges of oral administration and elicitation of immune 
response. A combination of concepts and techniques from polymer chemistry, drug 
delivery, and immunology were employed to create a two component oral delivery 
strategy for nanovaccines containing protein antigen. 
This multi-component system was a collaborative effort, comprised of 
polyanionic microgel matrix encapsulating polyanhydride nanoparticles. Development of 
the encapsulated nanoparticles have been investigated in great detail by Professor Balaji 
Narasimhan and his research team at Iowa State University for use as vaccine platforms 
via subcutaneous or intranasal administration. Nanoparticles based on poly(sebacic acid) 
(SA), and 1,6-bis(p-carboxyphenoxy)hexane (CPH) have demonstrated ability to stabilize 
encapsulated antigens, sustain protein release, and stimulate humoral and cellular 
response (1-5).  
The focus of the present work is the development of the microgel matrix designed 
to protect the polyanhydride nanoparticles and their sensitive antigenic payload through 
gastric conditions and subsequently release nanoparticles upon exposure to intestinal 
conditions. Inspired by the use of crosslinked hydrogel networks for pH-sensitive protein 
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delivery (6, 7), polyanionic microgels were synthesized using methacrylic acid (MAA) 
and poly(ethylene glycol) monomethyl ether monomethacrylate (PEGMMA). 
Microencapsulation of the nanoparticles was done via a pH-triggered assembly process. 
Several formulations were synthesized by varying the feed ratios of the polyanhydride 
nanoparticles and exploring two different polyanhydride compositions: Poly(SA) and 
20:80 CPH:SA. Formulations were evaluated for successful synthesis, pH-responsiveness 
and sustained release of protein antigen, in vitro cytocompatibility and 
immunostimulatory capacity. Finally, the ability of PROMPT composite microgels to 
stimulate systemic and mucosal protective antibody response was evaluated in vivo.  
The following specific aims were addressed in this research:  
 
Specific Aim 1: Design, synthesize and characterize pH-responsive microencapsulation 
systems for the oral delivery of polyanhydride nanoparticles to sustain subunit antigen 
delivery (Chapter 4). 
 
Specific Aim 2: Evaluate the cytocompatibility and immunostimulatory properties of the 
composite vaccine carriers in vitro (Chapter 5). 
 
Specific Aim 3: Perform an in vivo evaluation of microencapsulated nanoparticles to 
induce antigen-specific systemic and mucosal antibody protection after oral 
immunization (Chapter 6).  
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Chapter 4:   Development and Characterization of Microencapsulation 
Systems for the Oral Delivery of Nanoparticles 
4.1 INTRODUCTION 
The Global Vaccine Action Plan (GVAP), published in 2012, designated non-
syringe delivery mechanisms as a research priority for the development of next-
generation vaccines that are “more effective, less expensive and easier to manufacture 
and deliver” than traditional vaccines (1). Oral delivery is easily the safest and most 
practical alternative for vaccine administration.  Additionally, the oral route enables 
stimulation of humoral and cellular immune responses at both systemic and mucosal sites 
to establish broader and long-lasting protection (2-4). 
However, with the exception of a few successful live attenuated oral vaccines, 
administration of bolus oral doses is ineffective at stimulating protective systemic or 
mucosal responses. The oral route poses a myriad of challenges to overcome, including 
pH-dependent or enzymatic denaturation of the vaccine in the stomach, achieving 
adequate uptake of antigen in the small intestine, and delivering an appropriate dosage to 
elicit protection instead of tolerance (5, 6).  Furthermore, while traditional vaccines 
consist of attenuated or inactivated pathogens, not all organisms can be attenuated and 
those that can often impose safety risks including inflammation, uncontrolled replication, 
and disease in immunocompromised patients (7, 8).  
Thus, researchers have turned to subunit vaccines, such as protein antigens, to 
improve vaccine safety. However, especially in the context of the oral route, protein 
antigens are fragile structures that can be both weakly immunogenic and poorly absorbed, 
requiring carefully designed delivery systems to provide protection and enhance the 
resulting immune response (7, 9).  
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We present here a multi-component strategy to deliver subunit vaccines via the 
oral route.  In their core, polyanhydride nanoparticles (PNPs) based on 1,6-bis-(p-
carboxyphenoxy)hexane (CPH) and sebacic acid (SA) serve simultaneously as adjuvant 
and delivery vehicles of protein antigen. Polyanhydride nanoparticles have demonstrated 
substantial promise as drug and antigen delivery vehicles (10-12). Polyanhydrides are 
biodegradable polymers that have been shown to stabilize a variety of protein and peptide 
antigens, have tailorable sustained antigen release kinetics, and possess both excellent 
biocompatibility and adjuvant properties (13, 14).  
To achieve selective delivery of a depot of PNPs to the small intestine, particles 
are incorporated into pH-responsive microgels synthesized by a self-assembly process. 
The pH-responsive polymer is composed of poly(methacrylic acid) (PMAA) with 
poly(ethylene glycol) (PEG) tethers, designated as P(MAA-g-EG). Crosslinked P(MAA-
g-EG) hydrogels and other similar complexation hydrogel formulations have been 
developed for oral delivery of therapeutic proteins, such as insulin (15, 16), interferon β 
(17), TNF-α (18), and even for the design of oral vaccine formulations (19, 20). 
In this work, design of a self-assembled instead of crosslinked hydrogel enables 
facile inclusion and release of much larger payloads. Polymeric coating of nanoparticles 
for oral vaccine delivery has been investigated previously for chitosan (21, 22) and 
PLGA nanoparticles (23). Delivering nanoparticles encapsulating antigen, instead of 
antigen alone, provides the additional feature of the sustained release of the entrapped 
antigen. The depot effect is known to be an effective mechanism for conventional 
adjuvants, such as alum and incomplete Freund adjuvant (24).  
The composite platform is referred to as Polyanhydride-Releasing MicroParticle 
Technology, or PROMPT. Design of PROMPT for oral vaccine delivery is described in 
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Figure 4.1. In this work, the synthesis and characterization of PROMPT formulations are 
described. Additionally, pH-dependent dynamic release and sustained release kinetics of 
the model antigen, ovalbumin (ova), were evaluated from PROMPT microgels 
synthesized with varying feed ratios of antigen-loaded nanoparticle using two different 
polymer chemistries, Poly(SA) and 20:80 CPH:SA, to evaluate the composite microgels 
as an oral vaccine platform.  
 
 
 
 
Figure 4.1 Design for oral delivery of vaccines for immunization at the intestinal mucosa. 
Microencapsulation using a copolymer of poly(methacrylic acid) and 
poly(ethylene glycol) protects polyanhydride nanoparticles from the harmful 
effects of the low pH and enzymatic destruction in the stomach and and 
enables selective release in the upper small intestine.  
 
  
78 
4.2 EXPERIMENTAL METHODS 
4.2.1 Materials 
All reagents were used as received. Methacrylic acid (MAA), 1-
hydroxycyclohexyl phenyl ketone (Irgacure® 184), Span® 80, CdSeS/ZnS alloyed 
quantum dots (λem=525nm) and albumin from chicken egg white were obtained from 
Sigma-Aldrich (St.Louis, MO). Polyethylene glycol monomethyl ether methacrylate 
(PEGMMA, ME 1000) was purchased from Polysciences Inc. (Warrington, PA), and 
TAMRA-cadaverine obtained from Biotium (Fremont, CA). EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride) (EDC), and N-Hydroxysuccinimide 
(NHS) were obtained from Thermo Fisher Scientific (Waltham, MA). All other solvents 
and buffers were also obtained from Thermo Fisher Scientific (Waltham, MA). 
Polyanhydride polymers were synthesized by collaborators at Iowa State University.  
4.2.2 Synthesis  
4.2.2.1 Synthesis of P(MAA-g-EG) 
P(MAA-g-EG) polymer was synthesized by a photoinitiated free-radical 
polymerization. MAA and PEGMMA were added in a 1:1 molar ratio of hydrogen 
bonding groups in a 1:1 (w/w) solution of deionized water and ethanol to yield a final 1:5 
total monomer to solvent ratio. The photoinitiator Irgacure® 184 was added at a 1 wt % 
with respect to total monomer content. The mixture was homogenized by sonication and 
then purged of oxygen, a free-radical scavenger, by nitrogen purging the sealed flask for 
20 minutes. Polymerization was initiated using a Dymax® BlueWave 200 UV point 
source (Dymax, Torrington, CT) at 150 mW/cm
2 
intensity, and allowed to proceed for 2 
hours while stirring.  
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Linear polymer was purified from unreacted monomer by inducing polymer-
ionomer collapse. The pH of the polymer solution was adjusted to 10 by addition of 50% 
sodium hydroxide solution. The polymer was collapsed while keeping the pendant groups 
ionized by lowering the dielectric constant of the suspension, in this case by addition of 
acetone, which caused immediate flocculation and sedimentation of the polymer. 
Polymer was collected by centrifugation at 4,000 rcf for 10 min and supernatant 
containing unreacted monomer removed. The pellet was resuspended in water and the 
process was repeated three times. The polymer solution was neutralized, dialyzed against 
deionized water in 3.5 kDA molecular weight cutoff dialysis tubing (Spectrum Labs, 
Rancho Dominguez, CA) for 10 water changes, and then freeze dried and stored at room 
temperature with desiccant. 
4.2.2.2 Synthesis of Polyanhydride Polymers 
Synthesis of diacids of 1,6-bis(p-carboxyphenoxy)hexane (CPH), prepolymers of 
sebacic acid (SA) and CPH, as well as homopolymers of sebacic acid and the copolymer 
with molar composition 20:80 CPH:SA, were performed by collaborators at Iowa State 
university, as previously reported (25, 26). A typical reaction to yield each polymer 
precursors is described briefly. Prepolymers of both SA and CPH were refluxed in an 
excess of acetic anhydride for 30 and 60 minutes, respectively, under nitrogen. Acetic 
acid was removed by evaporation at 50
o
C. SA prepolymer was purified by addition of 
chloroform, followed by addition of 1:1 mixture of anhydrous ethyl ether and petroleum 
ether. The solution was stirred for 10 minutes, filtered and dried under vacuum overnight. 
CPH prepolymer was filtered, washed with ethyl ether and then vacuum dried overnight.  
Poly(SA) and 20:80 CPH:SA were synthesized by melt polycondensation of 
acetylated prepolymers at 180
o
C under vacuum for 90 minutes. Resulting polymer was 
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dissolved in methylene chloride and precipitated in dry petroleum ether. Purified polymer 
was dried under vacuum overnight. The chemical structure of all polymers was verified 
by 
1
H NMR and molecular mass determined using gel permeation chromatography prior 
to use. 
4.2.2.3 Polyanhydride Nanoparticle Synthesis 
Polyanhydride particles were synthesized by anti-solvent nanoencapsulation as 
described previously (25, 26). For these studies 20:80 CPH:SA or Poly(SA) (20 mg/mL) 
was dissolved in methylene chloride with Span® 80 (1% v/v) and the desired 
encapsulating agent: either ova (5% w/w) or quantum dots (1% v/v).  The polymer 
solution was sonicated at 50 Hz for 30 seconds using a probe sonicator (Fisher Scientific 
Model 50 Sonic Dismembrator) and then rapidly poured into a pentane bath at a solvent 
to non-solvent ratio of 1:250. Resulting particles were collected by filtration (Whatman 
50, Fisher Scientific) and characterized using scanning electron microscopy (SEM, Zeiss 
Supra40 Scanning Electron Microscope, Oberkochen, Germany).  
 
4.2.2.4 PROMPT Composite Microgel Synthesis  
Antisolvent precipitation was used to produce particle dispersions of 
polyanhydride nanoparticles stabilized by P(MAA-g-EG). Linear P(MAA-g-EG) polymer 
was dissolved in deionized water (pH 6) at 20 mg/mL. Polyanhydride nanoparticles were 
added at varying ratios (10% or 20 wt% relative to polymer content), and sonicated at 50 
Hz for 30 seconds to achieve a dispersed solution. HCl, at 0.1N concentration, was used 
as the anti-solvent, added to the polymer-nanoparticle dispersion at a volumetric ratio of 
1:100. Upon addition of solvent into the antisolvent phase, particles rapidly formed and 
began to flocculate.  
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Flocculated particles were collected by centrifugation (4500 rcf, 5 min), and then 
freeze-dried. The final particles were acquired by crushing the particle pellet with a 
mortar and pestle to obtain a fine powder. Synthesized microgel formulations are 
described in Table 4.1  
Table 4.1 Summary of PROMPT composite microgel formulations synthesized  
Notation 
Polyanhydride 
Nanoparticle Composition 
Nanoparticle Feed Ratio 
(wt% of polymer) 
10% Poly(SA) Poly(SA) 10 
20% Poly(SA) Poly(SA) 20 
10% 20:80 CPH:SA 20:80 CPH:SA 10 
20% 20:80 CPH:SA 20:80 CPH:SA 20 
 
4.2.3 Characterization 
4.2.3.1 Copolymer Characterization 
Copolymer composition was verified by 
13
C-NMR using a Varian DirectDrive 
600MHz nuclear magnetic resonance spectrometer (Palto Alto, CA). A minimum of 50 
mg of dried polymer was dissolved in 700 µL of D2O. All NMR Spectra were analyzed 
using MestReNova Software.  
Polymer molecular weight was determined by gel permeation chromatography 
(GPC) using a Malvern Viscotek TDAmax Triple Detection SEC System (Malvern 
Instruments, Malvern, Worcestershire, UK), equipped with an A6000M column. Samples 
were dissolved in 0.1M Na2HPO4 to a final concentration of ~4 mg/mL for 1 hour prior 
to analysis at 30
o
C. For all samples, an injection volume of 100 ul and a flow rate of 1.0 
mL/min were used. Molecular weight data was calculated using OmniSEC software.  
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4.2.3.2 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was used to examine the surface 
morphology, particle shape, and size of microparticle formulations in the dried state. 
SEM samples were prepared by dusting carbon-tape covered aluminum stubs with 
lyophilized and crushed microgels. Samples were coated with 12 nm of 
platinum/palladium using a Cressington 208HR sputter coater (Watford, England, UK). 
Coated samples were imaged with a Zeiss Supra 40VP Scanning Electron Microscope 
(Oberkochen, Germany).  
4.2.3.3 Confocal Microscopy 
Confocal microscopy was used to verify nanoparticle incorporation during 
PROMPT Synthesis. P(MAA-g-EG) was labeled with TAMRA-cadaverine prior to 
PROMPT synthesis by an EDC-NHS reaction. To accomplish this reaction, 200 mg 
purified P(MAA-g-EG) was mixed with 50 mg EDC and 80 mg NHS in DI water for 2 
minutes, prior to the addition of 52 µL of  a 10 mg/mL TAMRA-cadaverine solution. The 
reaction solution was then incubated for two hours at room temperature. The labeled 
P(MAA-g-EG) polymer was washed three times using the ionomer collapse procedure 
and then freeze-dried.  
Nanoparticle formulations were synthesized as previously described to 
encapsulate 1%(w/w) 525 nm quantum dots. The fluorescent P(MAA-g-EG) and 
nanoparticle formulations were used in the PROMPT synthesis procedure previously 
described. Fluorescent microgels were sprinkled onto a coverslip and imaged by an 
FV10i-DOC inverted laser-scanning confocal microscope (Olympus, Tokyo, Japan) using 
a built-in UPLSAPO 60x phase contrast oil immersion objective (NA=1.35). All settings 
and image adjustments were maintained for all images obtained.  
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4.2.3.4 Fourier Transform Infrared Spectroscopy  
Fourier transform infrared spectroscopy (FTIR) spectra was used to investigate 
the molecular structure of the polymer starting materials, P(MAA-g-EG) and 
polyanhydride polymers, as well as the PROMPT composite microgels.   All spectra were 
collected from 2500-650 cm
-1
 as the average of 64 scans on a Nicolet iS10 FT-IR 
Spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) outfitted with Smart iTX 
accessory for measurement in ATR mode. 
4.2.3.5 pH-dependent dissociation 
Dissociation of the composite microgels was verified by microscopy using an 
Olympus IX73 inverted microscope (Olympus, Tokyo, Japan). Microgels containing 
quantum-dot loaded nanoparticles were hydrated in 0.1M HCl, and then 50μL of sodium 
hydroxide was added to adjust the pH to 6.5.  Bright field and fluorescence images of the 
dissociation were captured using the 10x objective.  
4.2.4 Protein Release Kinetics 
4.2.4.1 Ovalbumin release kinetics from polyanhydride nanoparticles 
In vitro release kinetics of ovalbumin from 20:80 CPH:SA and Poly(SA) 
formulations was performed using a micro bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific). Nanoparticles were suspended at 10 mg/mL in phosphate buffered 
saline (PBS, pH 7.4) with 0.01% sodium azide and maintained at 37
o
C under constant 
agitation for the duration of the study. Release samples were collected at 1 hour, and on 
days 1, 2, 3, 5, 10, 15, 20 and 30 to evaluate sustained release of ova from the 
nanoparticles. To collect samples, nanoparticles were centrifuged at 10,000 rcf for 10 
minutes, and supernatant collected and replenished with fresh buffer. Samples were 
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stored at 4
o
C until analysis. After 30 days, the remaining encapsulated protein was 
extracted by addition of sodium hydroxide to a final concentration of 50 mM. 
Experiments were performed in triplicate.  
 
4.2.4.2 Ovalbumin release kinetics from PROMPT composite microgels 
In vitro release kinetics of ovalbumin from PROMPT formulations were 
performed using a micro bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). 
PROMPT formulations were suspended at 1mg/mL in phosphate buffered saline (PBS, 
pH 7.4) with 0.01% sodium azide and maintained at 37
o
C under constant agitation for the 
duration of the study. Release samples were collected at 1 hour, and on days 1, 2, 3, 5, 
10, 15, 20 and 30 to evaluate sustained release of ova. At each time point, suspensions 
were centrifuged at 4000 rcf for 10 min, and a 2 mL aliquot collected and replaced with 
fresh PBS. Samples were stored at 4
o
C until analysis. After 30 days the remaining 
encapsulated protein was extracted by addition of sodium hydroxide to a final 
concentration of 50 mM. Experiments were performed in triplicate.  
 
4.2.5 Dynamic Release of Ovalbumin from PROMPT formulations 
4.2.5.1 Experimental setup  
The pH-dependent release of ovalbumin from PROMPT composite microgels was 
evaluated using a two-stage dissolution protocol to simulate the transition from gastric to 
intestinal conditions. A Distek 2100 B Dissolution System (Distek, Inc., North 
Brunswick, NJ) with paddle apparatus was used according to United States Pharmacopeia 
(USP) 29 Chapter 711 Apparatus II guidelines. Small volume dissolution vessels (100 
  
85 
mL) were coated with Sigmacote siliconizing reagent (Sigma-Aldrich) to prevent protein 
adsorption and covered over the course of the experiment to minimize buffer evaporation.  
Fasted state simulated gastric fluid (FaSSGF) and fasted state simulated intestinal 
fluid (FaSSIF) were prepared according to the manufacturer’s instructions 
(Biorelevant.com, London, England). For 500 mL of FaSSGF buffer, 1.0g of NaCL was 
dissolved in 450 mL of DI water. The pH was adjusted to 1.6 by addition of hydrochloric 
acid and then total volume made up to 500 mL. Half of the volume was used to dissolve 
0.03 g the FaSSIF/FeSSIF/FaSSGF biorelevant powder, and then the volume completed 
to 500 mL with the remaining HCl/NaCL solution. FaSSIF was prepared at 2x 
concentration by dissolving 0.420 g sodium hydroxide (NaOH; Fisher Scientific, 
Waltham, MA), 3.438 g sodium phosphate anhydrous (NaH2PO4; Sigma Aldrich, St. 
Louis, MO), and 6.816 g sodium chloride (NaCl; Fisher Scientific, Waltham, MA) in 450 
mL DI water. The pH was adjusted to 6.9 by addition of sodium hydroxide. 
Subsequently, 250mL of the NaOH/NaH2PO4/NaCl solution was used to dissolve 2.240g 
of the FaSSIF/FeSSIF/FaSSGF biorelevant powder. The pH of the FaSSIF buffer was 
adjusted by addition of sodium hydroxide such that a 1:1 ratio of the FaSSGF and  
FaSSIF solutions (0.5 mL of each) reached a final pH of 6.5, before the volume of 
FaSSIF was brought up to 500 mL by addition of the remaining NaOH/ NaH2PO4/NaCl 
solution. Both buffers were stored at room temperature and used within the recommended 
48 hour window.  
4.2.5.2 Dynamic Release Protocol 
Dynamic release was evaluated from 10 mg of either 10% Poly(SA), 20% 
Poly(SA), 10% 20:80 CPH:SA or 20% 20:80 CPH:SA carefully added into dissolution 
vials with 30 mL of FaSSGF buffer. At 10, 20, and 20 minutes, 1mL aliquots were 
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removed with a sampling needle fit with 10 µm filters and replaced with FaSSGF to 
maintain constant volume. After 30 minutes in gastric conditions, 30 mL of FaSSIF 
solution was added to the dissolution vessel, and samples taken in the same manner at 10, 
20, 30, 60, 120, 180, and 240 minutes with volume replacement by a 1:1 mixture of 
FaSSGF:FaSSIF. Impellers were set to 100 rpm to maintain constant agitation, and 
dissolution apparatus water bath maintained at 37
o
C for the duration of the experiment. 
Experiments were performed in triplicate.  
4.2.5.3 Ovalbumin Specific Enzyme-Linked Immunosorbent Assay (ELISA)  
Release samples were analyzed with an ovalbumin sandwich ELISA. High-
binding 96-well plates (Costar 3590) were coated with 100 µL monoclonal anti-chicken 
egg albumin (Sigma Aldrich, A6075 clone OVA-14) diluted 1:2000 in PBS overnight at 
4
o
C. Plates were washed three times with a washing buffer comprised of PBS with 0.05% 
tween20 (PBST), blocked for 2 hours at room temperature with a 2% BSA solution in 
PBST, and then washed three times with PBST again. 100 µL of each release sample was 
added in triplicate and incubated overnight (18 hours) at 4
o
C. Serial dilutions of chicken 
egg white ovalbumin (Sigma Aldrich, A5503) were included in each ELISA plate to 
establish a standard curve. Following incubation, plates were washed three times with 
PBST. Rabbit anti-chicken egg albumin polyclonal antibody (Sigma Aldrich, C6534) at 
1:10,000 dilutions in PBST was added to each well and incubated for 1 hour at 37
o
C. 
Plates were washed three times with PBST and alkaline phosphatase-conjugated goat 
anti-rabbit IgG detecting antibody (Sigma Aldrich, A3687) was used at 1:10,000 dilution, 
100 µL per well, and incubated for 1 hour at 37
o
C. Plates were washed three times with 
PBST. Color development was achieved by addition of 100 µL p-nitrophenyl phosphate 
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(PNPP) substrate solution (Thermo Fisher Scientific). Absorbance was measured at 405 
nm on a Biotek Cytation 3 Cell Imaging Multi-Mode Reader (Winoosky, VT, USA). 
4.3 RESULTS AND DISCUSSION 
4.3.1 Polymer Characterization 
As discussed previously, polymer samples were synthesized by free radical 
polymerization and the ensuing materials were tested by a variety of techniques. The 
composition of the P(MAA-g-EG) copolymer (Figure 4.2) was verified by 
13
C NMR 
spectroscopy (Figure 4.3). The final polymer composition is based upon both the molar 
feed ratio and reactivity ratio of the monomer components. Relative molar composition 
of polyethylene glycol and methacrylic acid were calculated according to Table 4.2. 
Methyl groups in the polymer backbone from both PEG and MAA groups correspond to 
the peak centered at 17.3 ppm, while terminal methyl groups on the PEG tethers appear at 
58 ppm. Peak assignment was confirmed using 2D HSQC NMR. The molar percent of 
PEG chain was calculated as the ratio of terminal PEG methyl groups over the total 
backbone methyl groups from both MAA and PEG groups. The MAA molar fraction of 
the copolymer was determined as (1 – molar fraction of PEG). The resulting P(MAA-g-
EG) copolymers were determined to have MAA content between 91.4% and 94.3%, or 
95.6-98.6% of the MAA added in the feed ratio, as reported in Table 4.3. 
The molecular weight of P(MAA-g-EG) copolymer was determined using GPC 
and is summarized in Table 4.4. The resulting polymer had an average molecular weight 
range between 55-57 kDa with polydispersity indices of 2.1-2.6, which are consistent 
with the reported literature for free radical polymerization  (27, 28).  
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Figure 4.2 Representative structure of one unit of P(MAA-g-EG)  
 
 
 
 
 
 
 
 
 
 
  
89 
Table 4.2 Representative calculations to determine relative molar composition of 
P(MAA-g-EG) copolymer using 
13
C NMR spectra analysis. Relative molar 
calculations refer to the integrals of the peaks labeled in Figure 4.1: a: 58 
ppm, PEG terminal methyl groups; f: 17.3 ppm backbone methyl groups. 
 Peak 
Assignment 
(ppm) 
Integral Relative 
moles 
calculation 
Molar % 
in Feed 
Calculated 
Molar % 
MAA 
 
17.3 (f)  15.29 ∫ f − ∫ a
∫ f
 
 
95.6% 93.5% 
PEGMMA 58 (a) 1.0 ∫ a
∫ f
 
4.4% 6.5% 
 
 
 
Figure 4.3 Representative 
13
C NMR spectra of P(MAA-g-EG) in D2O 
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Table 4.3 Copolymer composition of P(MAA-g-EG) synthesized by free-radical 
polymerization as determined by 
13
C NMR 
 Batch 1 Batch 2 Batch 3 
%MAA 93.4 94.3 91.4 
%PEGMMA 6.5 5.7 8.6 
 
Table 4.4 Molecular weight of P(MAA-g-EG) determined by GPC 
Sample Mz Mw Mn Mw/Mn Rh (nm) 
1 121,699 55,638 25,943 2.145 5.79 
2 126,670 55,297 21,152 2.616 5.64 
3 126,829 57,159 23,528 2.429 5.79 
4.3.2 Microgel Morphology  
SEM was used to confirm and evaluate the self-assembled composite systems, 
synthesized using two different polyanhydride nanoparticles, Poly(SA) and 20:80 
CPH:SA, at two different feed ratios, 10 and 20%. The self-assembly process resulted in 
disperse particle flocs that were subsequently collected by centrifugation and dried by 
lyophilization. The dried powder was robust and able to be crushed into a fine powder 
with mortar and pestle. All four formulations exhibit similarly irregular morphology 
resulting from the preparation process, as shown in Figure 4.4. SEM images at 5000x 
indicated  unentrapped nanoparticles associated with the microgel surface, with both 20% 
formulations appearing to have more surface-association than microgels with 10% 
nanoparticles. 
Confocal microscopy was used to confirm that nanoparticles were incorporated 
throughout the microgels during the synthesis process. Both the P(MAA-g-EG) and 
nanoparticles were modified with fluorescent agents prior to microgel synthesis, prepared 
in the same manner as unmodified microgels, and corresponding z stack images obtained. 
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The xy and yz orthogonal projections from a z-plane in the middle of the particles, shown 
in Figure 4.5, confirm that the nanoparticles are incorporated throughout the self-
assembled microgels for both 10% and 20% nanoparticle feed ratios.  
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Figure 4.4 Representative SEM micrographs of PROMPT composite microgels 
synthesized with 10 and 20% feed ratios of Poly(SA) and 20:80 CPH:SA 
nanoparticles. 
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Figure 4.5 Representative images from z-stack scans of PROMPT composite microgels 
synthesized with 10 and 20% feed ratios of Poly(SA) nanoparticles. The xy 
and yz orthogonal projections confirm nanoparticle incorporation 
throughout self-assembled microgels.  
4.3.4 Fourier Transform Infrared Spectroscopy 
 Fourier Transform Infrared spectroscopy (FTIR) spectra were obtained for linear 
P(MAA-g-EG), poly(SA), 20:80 CPH:SA, as well as the four PROMPT composite 
microgel formulations (Figure 4.6). FTIR spectra of P(MAA-g-EG) dissolved in acidic 
and neutral pH conditions prior to freeze drying confirm the macromolecular changes the 
polymer undergoes in response to changes in environmental pH – namely the ionization 
of the carboxylic acid groups of the MAA. 
Characteristic functional groups were consistent with previously reported spectra (29-
31) and are summarized in Table 4.4. The region between 1750-1500 cm
-1
 generated the 
most information about the pH-dependent macromolecular changes. At pH 2, the 
carbonyl of the carboxylic acid appeared at 1717 cm
-1
. Ionization of the carboxylic acid 
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of the MAA group at neutral pH shifted the carbonyl peak towards 1640 cm
-1
 and 
resulted in the appearance of a strong C(=O)-O
-
 stretching peak. 
The FTIR spectra for the polyanhydrides appear in Figure 4.6B. The characteristic 
peak reported for poly(SA) is the asymmetric carboxyl stretching of the aliphatic 
anhydride bond at 1810 cm
-1
 and appeared in both the Poly (SA) and 20:80 CPH:SA 
spectra. Additionally, the 20:80 spectra contain the characteristic CPH peak at 1605 cm
-1
, 
indicative of the aromatic ring structure (32, 33).   
The FTIR spectra of the PROMPT formulations in Figure 4.6C contain peaks from 
both spectra, providing molecular evidence of the surface-adsorbed nanoparticles 
observed by SEM. All four formulations are similar, with the primary difference being 
the presence of the characteristic CPH peak at 1605 cm
-1
 in the 20:80 CPH:SA or its 
absence in the Poly(SA) based formulations. The presence of the P(MAA-g-EG) 
carboxylic acid peak at in the 1720-1700 cm
-1
 confirms the hydrogen bonding, or 
complexation of the polymer and nanoparticles, that drives the self-assembly process in 
acidic conditions.  
Table 4.5 Comparison of characteristic functional groups from FTIR spectra of P(MAA-
g-EG) hydrated at pH 2 and 7 prior to lyophilization 
Functional Group Reported 
Wavenumber 
Range (cm
-1
) 
pH 2.0 pH 7.0 
C=O stretching vibrations 1725-1650 1719 1654 
C(=O)-O
-
asymmetric stretching 1650-1550 - 1560 
O-CH2 symmetric deformation 1475-1445 1466 1447 
OH in plane bending + C-O 
stretching 
1440-1395 1388 1398 
O-H deformation 960-875 961 948 
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Figure 4.6 ATR-FTIR spectra of A) P(MAA-g-EG) hydrated in pH2 and pH 7 aqueous 
conditions prior to lyophilization, B) polyanhydride polymer formulations, 
and C) PROMPT composite microgels synthesized by pH-triggered self-
assembly of P(MAA-g-EG) and nanoparticle dispersions.  
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4.3.5 pH-Dependent Dissociation 
 The pH-dependent dissociation of microgels to release nanoparticles was 
observed after suspending composite particles in aqueous solution at pH 1.2 and then 
adjusting the pH to 6.5. Representative images of 20% Poly(SA) microgels demonstrate 
that particles remained intact in acidic conditions without observable release of the 
fluorescent payload encapsulated by the nanoparticles (Figure 4.7 A,C). Within one 
minute of addition of the sodium hydroxide to adjust the pH, microgels were mostly 
dissolved to release the nanoparticle payload (Figure 4.7 B,D). 
 
 
Figure 4.7 Representative microgel dissociation in intestinal pH conditions. Microgels 
remain intact at acidic pH (A,C) and dissociate to release the nanoparticle 
cargo in neutral pH conditions (B,D).  Scale bar: 200 µm 
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4.3.6 Ovalbumin Release Kinetics from Polyanhydride Nanoparticles 
The protein release kinetics from carrier systems is important in the design and 
optimization of drug and vaccine delivery vehicles. Release kinetics of ovalbumin from 
Poly(SA) and 20:80 CPH:SA nanoparticle was quantified using a microBCA assay, and 
are shown in Figure 4.8. Both formulations had very similar release kinetics with high 
initial burst releases, associated with the relatively high loading content (34). The burst 
release of the 20:80 CPH:SA was slightly lower, which correlated with previously 
reported trends that increased nanoparticle hydrophobicity slowed surface erosion and, 
therefore, decreased the release rate of encapsulated protein. After the initial burst, 
sustained release of ovalbumin continued with >95% of the encapsulated payload 
released from both formulations by day 30.  
The initial burst release of antigen can more rapidly induce a primary immune 
response, which could be advantageous for vaccine delivery (35). However, the antigen 
dose, particularly via the oral route, must fall within a narrow range, as either too low or 
too high a dose could result in tolerance instead of a protective response (6, 36). The 
controlled and sustained release of the antigen has been demonstrated to induce a 
stronger and more lasting humoral immune response, due to its persistence at the target 
location (37-39). 
The loading efficiency of the two nanoparticle chemistries was calculated by 
comparing the total mass of ovalbumin loaded into the nanoparticles, quantified after 
extraction, to the theoretical loaded amount introduced during nanoparticle synthesis. 
Encapsulation of Poly(SA) and 20:80 CPH:SA nanoparticles were approximately 85% 
and 68%, respectively, accounting for the difference in overall mass of ova (µg) released 
per mass of nanoparticles (mg), shown in Figure 4.8B.  
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Figure 4.8 Ovalbumin release kientics from polyanhydride nanoaprticles. A) Cumulative 
mass fraction of ovalbumin released from Poly(SA) and 20:80 CPH:SA 
nanoparticle formulations over the course of 1 month at pH 7.4 as detected 
by microBCA assay. B) Mass ovalbumin released normalized to total mass 
of nanoparticle (n=3 ± S.E.M.) 
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4.3.7 Ovalbumin release kinetics from PROMPT microgels  
Release of ova from PROMPT microgels was evaluated to determine i) the 
efficiency of the microencapsulation process and ii) the effect of microencapsulation on 
the ova release kinetics. Nanoparticle encapsulation efficiency from the microgel self-
assembly process was quantified by comparing the total protein released from PROMPT 
formulations, determined after extraction, to the total protein loaded into the respective 
nanoparticle formulation, as described in section 4.3.6. Encapsulation efficiency of 
PROMPT composite microgels synthesized with either 10% or 20% feed ratio of the 
Poly(SA) or 20:80 CPH:SA nanoparticles are shown in Figure 4.9.  
All of the formulations had roughly 40-50% encapsulation efficiency of the 
nanoparticles introduced during microgel self- assembly, except for 20% PolySA, which 
had an encapsulation efficiency of approximately 30% (Figure 4.9A). Interestingly, the 
increase in nanoparticle feed ratio significantly increased the incorporation of 20:80 
CPH:SA nanoparticles, but not the Poly(SA) nanoparticles.  The increased efficiency of 
20:80 CPH:SA nanoparticle inclusion is attributed to the more hydrophobic nature of the 
polymer composition, which would favor the hydrophobic environment created during 
microgel self-assembly. Conversely, the more hydrophilic PolySA nanoparticles would 
less favorably reside within that same hydrophobic environment. This less favorable 
interaction does not appear to affect encapsulation efficiency at a 10% nanoparticle feed 
ratio, however, does  reduce the encapsulation efficiency at the higher 20% feed ratio.    
PROMPT microgels exhibited a similar release trend of ova as the non-
encapsulated nanoparticles, undergoing an initial burst release and a subsequent sustained 
delivery (Figure 4.10). However, the burst release of all PROMPT microgel formulations 
was lower than that observed for the nanoparticle formulations alone, ~50% in microgels 
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compared to ~60-70% for nanoparticles. The P(MAA-g-EG) protection shows potential 
to   slow the solvent diffusion to nanoparticles, thereby mitigating the degree of burst 
release and enabling a more sustained delivery of antigen. However, it should be noted 
that these experiments do not match the physiological environment, where there are 
larger volumes and higher rates of fluid exchange, which can certainly affect the initial 
protein release kinetics (40).   
While nanoparticle chemistry primarily affected the encapsulation efficiency, it 
was the nanoparticle feed ratio that affected the burst release from the composite 
formulations. Microgels synthesized with 10% nanoparticle feed ratio exhibited higher 
fractional burst release compared to the 20% feed ratio. Dissociation is driven by the 
hydrophilic nature of the charged groups on P(MAA-g-EG) in neutral pH conditions. 
Accordingly, microgels synthesized with the lower nanoparticle feed ratio have higher 
P(MAA-g-EG) content per mass, facilitating a more rapid dissociation of the microgel 
and exposure of nanoparticle surface area.  
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Figure 4.9 Encapsulation of nanoparticles into PROMPT microgels during self-assembly. 
A)  Mass of nanoparticles normalized to mass of PROMPT microgels. B) 
Encapsulation efficiencies of PROMPT microgels based on nanoparticle 
feed ratios of 10% and 20% during self-assembly process. (n=3 ± S.E.M., 
p<0.05) 
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Figure 4.10 Ovalbumin release kinetics from PROMPT composite microgels. A) 
Cumulative mass fraction of ovalbumin released from PROMPT 
formulations synthesized with 10 and 20% feed ratios of either Poly(SA) or 
CPH:SA nanoparticle formulations over the course of 1 month at pH 7.4 as 
detected by microBCA assay. B) Mass ovalbumin released normalized to 
total mass of composite microgels (n=3 ± S.E.M., p<0.05) 
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4.3.8 Dynamic Release of Ovalbumin from PROMPT formulations 
To evaluate the potential of PROMPT formulations for oral delivery, a two-stage 
dissolution experiment was used to mimic the transit of the microgel through the acidic 
environment of the stomach into the more neutral environment of the upper small 
intestine using a USP Class II dissolution apparatus. Figure 4.11 demonstrates ova 
released from PROMPT formulations as A) fraction ovalbumin released and B) total µg 
protein release per mg of PROMPT. Negligible ova release was detected in the gastric 
conditions (0-30 minutes) for all formulations, due to that fact that i) polyanhydride 
hydrolysis occurs much more slowly in acidic conditions than neutral or basic 
environments (41), and ii) microgel complexation in acidic conditions minimize 
polyanhydride surface in contact with gastric environment. This result is promising as 
any premature release of the payload in the stomach would be degraded by acidic 
conditions and proteolytic enzymes and, consequently, be unable to exert any 
immunological/therapeutic effect.  
Immediately upon shifting to intestinal mimicking conditions, ova release was 
detected. Similar to experiments in PBS alone, microgels exhibited sustained release 
kinetics after the initial burst of protein. Microgels synthesized with 20% feed ratio of 
nanoparticles released more protein than the 10% microgels. Additionally, 20:80 
CPH:SA containing formulations released more ova than Poly(SA) microgels at the same 
feed ratio. Therefore, the increased incorporation efficiency for 20:80 CPH:SA into 
microgels offset both the lower encapsulation efficiency of ova into the nanoparticles and 
the slower release kinetics of the more hydrophobic 20:80 CPH:SA chemistry.  
 
  
104 
 
Figure 4.11 Ovalbumin release from PROMPT composite microgels after a two-stage 
dissolution protocol in simulated gastric conditions (0-30 minutes) and 
simulated intestinal conditions (30-270 minutes). (n=3 ± S.E.M, *p<0.05) 
4.4 CONCLUSIONS 
A novel self-assembled microgel was developed for depot delivery of polyanhydride 
nanoparticles. P(MAA-g-EG) polymer composition and molecular weight were verified 
by 
13
C NMR and GPC, respectively, and are consistent with previous literature. The 
P(MAA-g-EG) self-assembly process occured in a reversible pH-dependent fashion to 
encapsulate polyanhydride nanoparticles in acidic conditions and selective release in 
neutral pH conditions. SEM micrographs demonstrate a polydisperse population of 
microgels with nanoparticles adsorbed to the surface, while confocal microscopy 
confirmed nanoparticles are also incorporated throughout the microgel. FTIR confirmed 
macromolecular structures of both polyanhydride chemistries, pH-dependent 
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macromolecular changes in the P(MAA-g-EG) polymer, and incorporation of both 
materials into the self-assembled microgels.  
The composite PROMPT microgels released the model antigen, ova, in a pH-
controlled manner for gels synthesized at two feed ratios and with two nanoparticle 
chemistries: Poly(SA) and 20:80 CPH:SA. No ova release was detected from any 
formulation in gastric conditions. Upon transition to simulated intestinal conditions, 
microgels exhibited sustained ova release after the initial burst of protein. Increasing the 
feed ratio of nanoparticles into the microgels increased the total amount of ova delivered, 
as well as decreasing the observed burst release, likely due to the comparatively lower 
P(MAA-g-EG) content resulting in slower dissociation of the microgels.  
Overall, these results suggest that pH-dependent microencapsulation is a viable 
platform to achieve targeted intestinal delivery of polyanhydride nanoparticles.  
Furthermore, tailoring the feed ratio and composition of the nanoparticles allows for 
manipulation of protein release kinetics to potentially tailor a desirable balance between 
antigen burst release and subsequent persistence from nanoparticles to achieve an 
effective oral immunization strategy.  
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Chapter 5: In Vitro Evaluation of Microencapsulated Polyanhydride 
Nanoparticles: Cytocompatibility and Dendritic Cell Stimulation 
5.1 INTRODUCTION 
Evaluation of carriers in relevant in vitro models is an important step in the design 
vaccine and drug delivery platforms. Oral vaccine formulations will encounter a variety 
of cell populations, including epithelial cells of the small intestine, and if successfully 
transported, the diversity of immune cells in the Peyer’s patches. Establishing safety of 
the materials with relevant cell lines is important when considering translation of the 
materials to in vivo studies. Furthermore, in vitro assays can be used to evaluate the 
immunostimulatory potential of vaccine formulations.  
Dendritic cells (DCs) are among the most common and important antigen 
presenting cells in the gut-associated lymphoid tissue (GALT). DCs are principally 
responsible for inducing a primary immune response and enhancing secondary immune 
responses, processing and presenting antigenic fragments to B and T cells to initiate 
antigen-specific immunity. CD11c+ DCs are one of the subsets that reside in the sub-
epithelial dome region directly below the follicle associate epithelium, facilitating antigen 
uptake directly from M cells (1, 2).   
Antigen processing and presentation are activated by cellular engagement of 
pathogen-associated molecular patterns (PAMPs) with pattern recognition receptors on 
host cells (3, 4). Cell surface markers, such as MHC II, MHC I, and co-stimulatory 
markers such as CD80, CD86, CD40 are critical for antigen presentation by DCs to 
activate T cells and stimulate clonal expansion. Additionally, activated DCs may produce 
cytokines to mediate immune responses (3). Engagement of these APCs is critical in the 
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initiation of local and systemic immunity. Therefore, development of vaccine delivery 
carriers with immunostimulatory capabilities is important. 
In this work, the cytocompatibility of microencapsulated nanoparticle 
formulations, designated as Polyanhydride-Releasing Oral MicroParticle Technology 
(PROMPT), was evaluated in two representative cell lines: Caco-2 and RAW264.7. 
Caco-2 cells are a human derived colon carcinoma cell line widely used to evaluate drug 
absorption across the intestinal epithelium (5, 6). RAW264.7 cells are murine derived 
macrophages. Cytocompatibility studies were used to indicate the maximum tolerable 
concentration without disruption to metabolic activity and cell membrane integrity. The 
stimulatory abilities of PROMPT formulations were evaluated by expression of cell 
surface markers and cytokine secretion in bone-marrow derived murine dendritic cells.  
5.2 EXPERIMENTAL METHODS 
5.2.1 Materials  
Chemicals for composite microgel synthesis include methacrylic acid (MAA), 1-
hydroxycyclohexyl phenyl ketone (Irgacure® 184), and Span® 80 received from Sigma 
Aldrich (St. Louis, MO), and polyethylene glycol monomethyl ether methacrylate 
(PEGMMA, ME 1000) purchased from Polysciences Inc. (Warrington, PA All other 
solvents and buffers were also obtained from Thermo Fisher Scientific (Waltham, MA). 
Polyanhydride polymers were synthesized by collaborators at Iowa State University as 
previously described (7, 8). 
The materials required for cell culture include: RPMI 1640 from American Type 
Culture Collection (Manassas, VA), Dulbecco’s Modified Eagle Medium (DMEM), 
penicillin—streptomycin, and fetal bovine serum from Thermo Fisher Scientific 
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(Waltham, MA), L-glutamine from Sigma-Aldrich (St. Louis, MO) and granulocyte 
macrophage colony stimulating factor (GMCSF), purchased from PeproTech (Rocky 
Hill, NJ). Materials needed for flow cytometry included sodium azide and bovine serum 
albumin from Sigma Aldrich (St. Louis, MO), and unlabeled hamster IgG, antimouse 
CD16/CD32 antibody, PE-Cyanine7 CD11c Monoclonal Antibody (N418), 
phycoerythrin (PE) antimouse MHC II (I-Ek, clone 14-4-4S), fluorescein isothiocyanate 
(FITC)- conjugated antimouse CD80 (B7–1, clone 16–10A1), and respective isotypes 
PE-Cyanine7 Armenian Hamster IgG Isotype Control,  (PE) rat IgG2a κ Isotype Control, 
and FITC-conjugated Armenian Hamster IgG from eBioscience (San Diego, CA).  
 
5.2.2 Synthesis  
5.2.2.1 Polyanhydride Nanoparticle Synthesis 
Polyanhydride particles were synthesized by anti-solvent nanoencapsulation as 
described previously (7, 8). Briefly, either 20:80 CPH:SA or Poly(SA) (20 mg/mL) were 
dissolved in methylene chloride with Span80 ® (1% v/v). The polymer solution was 
sonicated at 50 Hz for 30 seconds using a probe sonicator (Fisher Scientific Model 50 
Sonic Dismembrator), then rapidly poured into a pentane bath at a solvent to non-solvent 
ratio of 1:250. Particles were collected by vacuum filtration (Whatman 50, Fisher 
Scientific), and characterized using scanning electron microscopy (SEM, Zeiss Supra40 
Scanning Electron Microscope, Oberkochen, Germany).  
5.2.2.2 PROMPT Composite Microgel Synthesis 
Antisolvent precipitation was used to produce particle dispersions of 
polyanhydride nanoparticles stabilized by P(MAA-g-EG). P(MAA-g-EG) dissolved in 
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deionized water (pH 6) at 20 mg/mL. Polyanhydride nanoparticles were added at 10 or 20 
wt% relative to P(MAA-g-EG), and sonicated at 50 Hz for 30 seconds to achieve a 
dispersed solution. The anti-solvent (0.1N HCl) was used at a volumetric ratio of 1:100. 
Upon addition of solvent into the antisolvent phase, particles rapidly form and begin to 
flocculate.  
Flocs were collected by centrifugation (4500 rcf, 5 min), then freeze-dried. The 
final particles were obtained by crushing the particle pellet with a mortar and pestle to 
achieve a fine powder. PROMPT formulations are denoted in this work as either 
PROMPT 20:80 CPH:SA or PROMPT Poly(SA) based on the nanoparticle cargo.  
5.2.3 Cytocompatibility  
Cytocompatibility of formulations was evaluated in Caco-2 colon 
adenocarcinoma cells and RAW 264.7 murine macrophages, obtained from American 
Type Culture Collection (ATCC, Rockwell, MD). Both cell lines were cultured in 
Dulbecco’s Modified Eagle’s medium, supplemented with 10% (v/v) FBS, 4mM L-
glutamine, and 1% (v/v) of an antibiotic solution (100 U/mL penicillin and 100 µg/mL 
streptomycin). Cells were sub-cultured in T-75 flasks at 37
o
C in a 5% CO2 environment. 
Media was refreshed every 72 hours and cells passaged at 80-90% confluence.  
For cytotoxicity studies, cell culture-treated 96-well polystyrene plates were 
coated with a 1:100 DPBS:fibronectin solution overnight at 4
o
C. The fibronectin solution 
was aspirated and wells rinsed once with DPBS prior to plating cells. Caco-2 and RAW 
264.7 cells were seeded at 25,000 and 20,000 cells per well, respectively, in completed 
DMEM without phenol red. Cells were maintained in the 96-well plates for 48 hours 
prior to undergoing any cytocompatibility experiments. 
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Solutions of microgels (PROMPT) and linear polymer (P(MAA-g-EG)), were 
prepared in DMEM without phenol red (+10 %FBS, 4mM L-glutamine, 1% P-S) at 
concentrations ranging from 0.25-1 mg/mL. Solutions of polyanhydride nanoparticles 
were also prepared in completed DMEM without phenol red at concentrations ranging 
from 50-200 µg/mL for nanoparticle formulations, corresponding to theoretical mass of 
nanoparticles encapsulated in the various microgel formulations. Media was carefully 
aspirated from all wells and replaced with either 100 µL of a formulation, unmodified 
growth media as a positive control, or water as a negative control and allowed to incubate 
for 4 hours with Caco-2 cells and 24 hours with RAW 264.7 macrophages at 37
o
C and 
5% CO2.  
Proliferation of cells after formulation exposure was used as an indicator of cell 
health, as measured by the CellTiter 96 ® AQueous One Solution Cell Proliferation MTS 
Assay (Promega, Madison, WI). Briefly, 20 µL of MTS assay solution was added to the 
treated wells and incubated for 90 minutes. After incubation, absorbance measurements 
were made at 490 nm and 690 nm, using a Biotek Cytation 3 Cell Imaging Multi-Mode 
Reader (Winoosky, VT, USA). Cytocompatibility is reported as relative cell proliferation, 
calculated by subtracting the background absorbance and normalizing to the average 
absorbance value of the positive control well, using the following equation: 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑝𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛 =
𝐴490−𝐴690
𝐴𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅
  (Eq 5.1) 
 
The integrity of the cellular membranes was evaluated using the Promega 
CytoTox One™ Homogenous Membrane Integrity Assay (Promega, Madison, WI). 
Twenty minutes prior to the end of the designated incubation period, plates were removed 
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from the incubator to equilibrate to room temperature. The  experimental supernatant (50 
µL) was transferred into a fresh black-walled 96-well plate and mixed gently with 50 µL 
of CytoTox One™ reagent for 30 seconds to ensure complete mixing of reagent and 
supernatant. The samples were incubated for an additional 10 minutes at room 
temperature and then 25 µL of assay stop solution was added to each well. Fluorescence 
measurements were made with an excitation wavelength of 560 nm and emission 
wavelength of 590 nm. Percent cytotoxicity was calculated by subtracting the culture 
medium background (media only, no cells) from all fluorescence values of experimental 
wells, and then normalizing the corrected experimental values relative to the negative 
control: 
 
% 𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = 100 𝑥 
(𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙−𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝑀𝑒𝑑𝑖𝑢𝑚 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
(𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝐿𝐷𝐻 𝑅𝑒𝑙𝑒𝑎𝑠𝑒−𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝑀𝑒𝑑𝑖𝑢𝑚 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
  (Eq 5.2 ) 
 
Results are reported as relative percent viability, calculated as 100% - % 
cytotoxicity. ANOVA analysis was used to compare multiple groups and a post-hoc 
Dunnett’s test was performed to confirm statistical significance of the experimental 
groups against the media only.  
5.2.4 Dendritic Cell Stimulation 
5.2.4.1 Dendritic Cell Culture and Stimulation 
Bone marrow derived dendritic cells were prepared from bone marrow cells 
isolated from femurs of Balb/c mice as described previously (9). Following mouse 
euthanasia, bones were excised, cleaned of muscle and tissue and cut at both ends.  The 
marrow was flushed out in complete medium (RPMI containing 1% l-glutamine, 1% 
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penicillin–streptomycin solution, 2% HEPES, 0.5% gentamicin, 0.1% β-mercaptoethanol, 
and 10% heat inactivated fetal bovine serum (FBS)) until bones appeared transparent. 
Cells were collected by centrifugation and suspended in complete medium supplemented 
with 10 ng/mL GMCSF. The cells were then placed in T-75 cell culture flasks in 10 mL 
of DC medium containing 10 ng/mL GMCSF and incubated at 37 °C under 5% CO2 
atmosphere. On day 3, 10 mL of fresh DC medium with 10 ng/mL GMCSF was added. 
On day 6, 10 mL of the culture medium was removed, cells collected by centrifugation 
and resuspended into 10mL fresh DC medium containing 10ng/mL GMCSF, then added 
back to the original flask. On day 8, DCs were removed from the flasks, counted, 
resuspended in fresh DC medium with 10 mg/mL GMSF, and transferred to 24-well 
plates (1 × 10
6 
cells/well) for 24 hours prior to stimulation.  
DCs were stimulated with either 750 μg/mL of PROMPT formulations 
synthesized with either 10% or 20% feed ratio of QD-loaded Poly(SA) or 20:80 CPH:SA 
nanoparticles. Non-stimulated (NS) DCs and 200 ng/mL lipopolysaccharide (LPS) were 
used as negative and positive controls, respectively. DC cultures were incubated with 
stimulants for an additional 48 h (37 °C, 5% CO2), at which time the supernatants and 
DCs were harvested for cytokine production and cell surface marker expression, 
respectively. Experiments were performed in triplicate. 
5.2.4.2 Flow Cytometry Evaluation of Cell Surface Markers 
The expression of cell surface markers CD11c, CD80, and MHC II were assessed 
after a 48 h incubation period of the DCs with the stimulation treatments. The adherent 
DCs were harvested from the culture dishes by scraping, placed in polystyrene tubes (BD 
FALCON™, Franklin Lakes, NJ), centrifuged (250 rcf, 10 min), and resuspended in Fc 
blocking solution consisting of PBS buffer with 0.1% anti-CD16/CD32, 0.1% unlabeled 
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hamster IgG, 0.1% sodium azide, and 0.1% bovine serum albumin. After blocking, the 
DCs were stained and fixed for evaluation of cell surface markers using monoclonal 
antibodies against CD11c, CD80, CD40, and MHC II. The samples were analyzed using 
a Becton-Dickinson LSRFortessa SORP Flow Cytometer (San Jose, CA) and FlowJo 
(TreeStar Inc, Ashland, OR). 
5.2.4.3 Cytokine Release 
After stimulation for 48 h, cell-free supernatants were assayed using a Bio-Plex 
Pro Mouse Cytokine Th1 Panel (IL-1β, IL- 2, IL-6, IL-10, IL-12p70, IFN-γ, and TNF-α; 
Bio-Rad, Hercules, CA) and a BioPlex200® Multiplex System. 
5.3 RESULTS AND DISCUSSION 
5.3.1 In Vitro Cytocompatibility   
5.3.1.1 Caco-2 Cytocompatibility 
Caco-2 cells were exposed to the microgel starting materials, P(MAA-g-EG) and 
polyanhydride nanoparticles, as well as the PROMPT composite microgels at various 
concentrations to determine the maximum concentration that could be tolerated without 
deleterious effects. The incubation time of four hours corresponds with the average 
intestinal residence time (10). 
The relative cellular proliferation of Caco-2 cells incubated with PROMPT 
microgel formulations, as compared to cell treated with media alone, ranged from 84%-
99% (Figure 5.1A). Interestingly, the only statistically significance effects on cellular 
proliferation were observed for the 10% Poly(SA) and 10% 20:80 CPH:SA microgel 
formulations, which have a higher content by mass of P(MAA-g-EG) than the 20% 
formulations. Studies have reported reduced viability in presence of ionizable 
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methacrylic acid groups, which can simultaneously acidify the pH of the cell culture 
media and chelate the positively charged calcium ions necessary for cellular function (11, 
12). These observations occurred only at 0.25 mg/mL for the 10% Poly(SA) 
formulations, but across all concentrations for 10% 20:80 CPH:SA. The mild cytotoxicity 
in 10% 20:80 CPH:SA formulations could be associated with the slightly increased 
hydrophobicity of the CPH:SA chemistry, which has been correlated with increased 
cytotoxicity (13). However, it is likely this effect is an artifact of the cell culture 
environment that would not transfer to the much more dynamic physiological 
environment of the small intestine, in which concentrations of the microgel formulations 
in contact with cells would not only be much lower, but also subject to constant liquid 
replacement, i.e. sink conditions. Nevertheless, a minimum of 80% relative proliferation 
was observed for all formulations, which has been set as an acceptable threshold to 
indicate cellular compatibility with biomaterials (12, 14, 15).  
Additionally, PROMPT formulations had negligible effects on cell membrane 
integrity as measured by lactose dehydrogenase (LDH) membrane integrity assay (Figure 
5.1B). The assay detects release of LDH from disrupted membranes into the culture 
media by addition of resazurin, which is converted by leached LDH into the detectable 
fluorescent agent resofurin.  Furthermore, P(MAA-g-EG) polymer and polyanhydride 
nanoparticles introduced at concentrations correlating to those evaluated for intact 
PROMPT microgels demonstrated no statistically significant effects on either cellular 
proliferation (Figure 5.1A,C) or membrane integrity (Figure 5.1C,D). This is a 
promising result as cells are more likely to encounter the dissociated components of the 
delivered PROMPT microgels in a physiological setting than the intact particles.  
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5.3.1.2 RAW 264.7 Cytocompatibility 
Similarly, RAW264.7 cells were exposed to composite microgel formulations of 
concentrations ranging from 0.25 – 1.0 mg/mL, as well as the individual components, 
linear P(MAA-g-EG) and nanoparticle formulations at their corresponding concentration 
ranges, but for an extended incubation time of 24 hours (Figure 5.2). Incubation time 
was extended for the macrophage cell line to indicate which concentrations and 
formulations would be viable for future internalization and stimulation experiments, 
which typically have incubations times of 24-48 hours (16, 17). 
Cellular proliferation relative to cells treated with cell culture media dropped as 
low as 60% for the highest concentration of PROMPT microgels. This was attributed to 
the static nature of the cell culture conditions, in which microgels resting on top of the 
cells can prevent nutrient exchange. However, there were no statistically significant 
effects at the lower concentrations and no deleterious effects on cell membrane integrity 
for the extended incubation period.  
The concentration-dependent effect on cellular proliferation is not concerning 
given that macrophage cells are not likely to encounter intact particles, especially at high 
concentrations, but instead the dissociated components, e.g. polyanhydride nanoparticles 
or P(MAA-g-EG) polymer chains. Both the nanoparticles and P(MAA-g-EG) polymer, at 
all tested concentrations, had no negative effects on proliferation of the macrophage cell 
line. There was, however, a reduction of cell viability as measured by membrane integrity 
for both nanoparticles formulations in a concentration-dependent fashion (Figure 5.2D), 
though cells still maintained well above the minimum 80% threshold.  
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Figure 5.1 Evaluation of in vitro cytocompatibility of Caco-2 colon adenocarcinoma cells 
after 4 hour incubations with PROMPT composite microgels, and the 
individual components P(MAA-g-EG) and PNP nanoparticles at varying 
concentrations. Cytocompatibility was determined by relative cellular 
proliferation, as measured by MTS proliferation assay (A,C), and membrane 
integrity, as measured by LDH release using Promega CytoTox One™  
Homogenous Membrane Integrity Assay (B,D). (n = 15 ± SD; * p<0.05) 
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Figure 5.2 Evaluation of in vitro Cytocompatibility of RAW264.7 murine macrophages 
after 24 hour incubations with PROMPT composite microgels, and the 
individual components P(MAA-g-EG) and PNP nanoparticles at varying 
concentrations. Cytocompatibility was determined by relative cellular 
proliferation, as measured by MTS proliferation assay (A,C), and membrane 
integrity, as measured by LDH release using Promega CytoTox One™  
Homogenous Membrane Integrity Assay (B,D). (n = 15 ± SD; * p<0.05) 
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5.3.2 Dendritic Cell Stimulation 
To evaluate activation of CD11c+ DCs by PROMPT formulations, flow 
cytometry was used to measure cell surface expression of co-stimulatory molecules 
CD80 and MHC II after 48 hours of stimulation. Additionally, supernatants were 
collected and analyzed for cytokine production. Non-stimulated groups with medium 
only acted as a negative control and LPS was used as a positive control. Prior to 
stimulation assays, the BMDC cultures were >80% positive for CD11c. Data are from 
three independent experiments, performed in triplicate. 
5.3.2.1 Cell surface marker expression 
 Previous studies have demonstrated the chemistry-dependent internalization and 
activation of DCs by polyanhydride particles (16, 17).  To assess immunostimulatory 
capabilities of composite PROMPT formulations, flow cytometry was used to measure 
nanoparticle internalization, as well as levels of cell surface expression of MHC II and 
co-stimulatory molecule CD80.  
DCs demonstrated significantly higher nanoparticle internalization after 
incubation with PROMPT formulations synthesized with a higher feed ratio of 
nanoparticles, demonstrating efficient dissociation of the microgels to release 
nanoparticles for uptake even in the static cell culture conditions (Figure 5.3). 
Formulations synthesized with Poly(SA) nanoparticles demonstrated the ability to better 
promote cell surface marker expression compared to the more hydrophobic 20:80 
CPH:SA containing formulations, consistent with previous observations (9, 17). As 
demonstrated in Figure 5.4, only the 20% Poly(SA) formulation significantly increased 
MHC II expression. However, both 20% Poly(SA) and 20% 20:80 CPH:SA formulations 
stimulated CD80 expression compared to non-stimulated DCs. Formulations synthesized 
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with 10% feed ratio of nanoparticles did not induce substantial cell surface marker 
expression compared to nonstimulated DCs, indicating that both composition and 
sufficiently high dose of nanoparticles are important considerations for DC stimulation.  
 
 
 
Figure 5.3 Analysis of nanoparticle internalization by bone marrow-derived dendritic cell 
after stimulation with PROMPT formulations (n = 3 ± SD *p<0.05) 
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Figure 5.4 Activation profiles of bone marrow-derived dendritic cells after stimulation 
with PROMPT formulations (n = 3 ± SD *p<0.05) 
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5.3.2.2 Cytokine secretion  
In addition to expression of surface markers for antigen presentation and 
activation, secretion of cytokines is essential to enhance CD4
+
 T cell activation and 
subsequent promotion of B-cell antibody production (18). Production of IL-2 and TNF-α 
was significantly higher for formulations synthesized with 10% instead of 20% feed ratio 
of the nanoparticles (Figure 5.5). Both TNF-α and IL-2 are important in early DC 
maturation and induction of T cell differentiation, and can ultimately influence the bias 
and magnitude of immune response (19, 20). Microgels synthesized with the lower 
nanoparticle feed ratio have higher P(MAA-g-EG) content per mass, therefore it is 
possible that the increase cytokine production induced by 10% microgels as compared to 
20% formulations is associated with the higher concentration of polymer, which could 
increase local acidification and trigger cytokine production in response to the local stress.  
All PROMPT formulations except for 20%Poly(SA) stimulated significant IL-6 
production, which is important in both innate and adaptive immune response by 
contributing to systemic inflammation and promoting humoral immune response (21, 22). 
Additionally, all PROMPT formulations stimulated IL-1β significantly compared to 
nonstimulated DCs, which also has implications for early stages of immune response to 
infections towards B-cell maturation and proliferation (19, 20).  
Secretion of IL-10, IL-12p70 and IFNγ were not as high as the other cytokine 
concentration in supernatant (<10pg/mL), but there were still differences between the 
particle treatments worth discussing (Figure 5.6). IL-10, which is associated with 
inhibition of pro-inflammatory cytokine production and can suppress immune response, 
demonstrated a response dependent on the relative amount of polymer in the 10% 
nanoparticle formulations, regardless of their chemistry. IL-12p70 demonstrated a 
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chemistry-dependent activation, favoring the mort hydrophobic 20:80 CPH:SA based 
formulations than those with Poly(SA), which has been observed in previous work (9). 
Lastly, all PROMPT formulations stimulated significant IFN-γ production compared to 
nonstimulated DCs. IFN-γ has been demonstrated to be important for mucosal defense to 
both viral and bacterial infections (23, 24).  
 
Figure 5.5 Cytokine secretion profiles from bone marrow-derived dendritic cells after 
stimulation with PROMPT formulations (n = 3 ± S.E.M *p<0.05) 
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Figure 5.6 Cytokine secretion profiles from bone marrow-derived dendritic cells after 
stimulation with PROMPT formulations (n = 3 ± S.E.M *p<0.05) 
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5.4 CONCLUSIONS 
PROMPT composite microgels formulations exhibited minimal-to-no effect on 
cellular proliferation and membrane integrity at concentrations as high as 1 mg/mL when 
evaluated with two model cell lines: Caco-2 intestinal epithelial cells and RAW 264.7 
macrophages. The cytocompatibility results are encouraging that PROMPT microgels are 
suitable carriers for oral vaccine applications, and defined tolerable concentrations for 
subsequent in vitro stimulation experiments with BMDCs. PROMPT formulations 
synthesized with 20% feed ratio of nanoparticles resulted in higher nanoparticle 
internalization as well as higher cell surface marker expression than those synthesized 
with 10% feed ratio of nanoparticles. PROMPT formulations were also able to stimulate 
cytokine production. These studies show that PROMPT composite microgel formulations 
are biocompatible and have the ability to release nanoparticles for internalization and 
activation of dendritic cells, which is known to be beneficial for the induction of 
efficacious immune responses.  
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Chapter 6: In vivo Evaluation of Microencapsulated Polyanhydride 
Nanoparticles as an Oral Vaccine Strategy 
6.1 INTRODUCTION 
Oral vaccination poses numerous advantages over the more commonly used 
parenteral route of administration. While parenteral vaccination can induce efficient 
systemic protection, injection is painful, invasive and cannot confer protective mucosal 
immunity (1). Most diseases for which vaccines are not yet available or elicit incomplete 
protection are associated with infectious agents that are restricted to mucosal membranes 
(2, 3). Therefore, it is desirable to generate local mucosal immune response that can 
impede infection and disease development.  
In addition to offering a less intrusive vaccine with higher patient compliance, 
oral administration mimics the immune response elicited by natural infection to induce 
both mucosal and systemic immune response. However, antigens administered via the 
mucosal route are generally poorly immunogenic. Additionally, antigen degradation and 
poor uptake into lymphoid tissue of the gastrointestinal (GI) tract have hindered 
development of oral vaccine formulations.  
The use of micro- and nano-particulate delivery systems has been explored to 
address the challenges associated with mucosal immunization (4, 5). Biodegradable 
polymeric particles have demonstrated promise, serving as antigen delivery vehicles and 
adjuvants by protecting the antigenic payload through transit, enhancing antigen 
presentation, and inducing protective immune response compared to soluble protein. 
Specifically, polyanhydride nanoparticle-based vaccines have shown the successful 
encapsulation and release of a diversity of antigens, activation of B and T cells, and 
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ability to induce both antibody and cell-mediated immune responses when administered 
intranasally (6-10).  
Polyanhydride nanovaccines have demonstrated their potential to elicit protective 
immunity after intranasal administration. However, oral delivery poses additional 
challenges that could impair translation of the technology.  Oral formulations are exposed 
to the gastric environment before reaching the intestine, where dilution in intestinal fluid 
can reduce the local antigen concentration and, therefore, increase the possibility of 
inducing tolerance. Polymeric coating has been investigated as a strategy to achieve oral 
delivery of nanoparticulate vaccines. Specifically, pH responsive Eudragit® and 
derivatives have been used to achieve nanoparticle protection and depot release for 
chitosan (11, 12) and PLGA nanoparticles (13),  respectively. The work reported herein 
used a copolymer of poly(methacrylic acid) (PMAA) with poly(ethylene glycol) (PEG) 
tethers, henceforth designated as P(MAA-g-EG), to facilitate oral delivery of 
polyanhydride nanoparticles. P(MAA-g-EG) possesses similar pH responsive behavior to 
Eudragit® formulations due to the presence of  MAA, which  enables the targeted 
intestinal release of the formulations. Inclusion of PEG tethers could provide additional 
advantages such as promoting mucoadhesion in the GI tract to facilitate nanoparticle 
release proximal to mucosal tissue for persistence, as well as improve likelihood of 
sampling by M cells in the small intestine. Additionally, PEG possesses molecular 
components that have been correlated with “pathogen-like behavior”, including backbone 
oxygen moieties and aliphatic carbon (9). 
The present research describes the in vivo evaluation of the composite 
nanoparticle-in-microgel formulation, designated as Polyanhydride-Releasing Oral 
MicroParticle Technology (PROMPT). A single immunization with formulations 
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containing the model antigen ovalbumin (ova) was administered. Ova-specific IgG and 
IgA production were measured as indicators of systemic and mucosal immune response, 
respectively. Additionally, production of inflammatory cytokines and a histopathological 
analysis of critical organs for filtration and purification, specifically the liver and kidney, 
were assessed to provide insight on potentially deleterious effects of PROMPT vaccine 
formulations.  
6.2 EXPERIMENTAL METHODS 
6.2.1 Materials 
All reagents were used as received, unless specified. Chemicals for composite 
microgel synthesis include methacrylic acid (MAA), 1-hydroxycyclohexyl phenyl ketone 
(Irgacure® 184), Span® 80, and albumin from chicken egg white were obtained from 
Sigma-Aldrich (St.Louis, MO), and polyethylene glycol monomethyl ether methacrylate 
(PEGMMA, ME 1000) was purchased from Polysciences Inc. (Warrington, PA). Goat 
serum, trypsin inhibitor type II, phenylmethylsulfonyl fluoride (PMSF), pefabloc SC, 
ethylenediaminetetraacetic acid (EDTA), bovine serum albumin (BSA) p-nitrophenyl 
phosphate substrate, diethanolamine substrate buffer and gelatin from cold water fish skin 
were obtained from Sigma Aldrich (St. Louis, MO). All other solvents and buffers were 
also obtained from Thermo Fisher Scientific (Waltham, MA). Polyanhydride polymers 
were synthesized by collaborators at Iowa State University. 
6.2.2 Animals 
All animal experiments were conducted as approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of Texas at Austin. Female Balb/c 
mice, ages 6-8 weeks old, were obtained from The Jackson Laboratory (Bar Harbor, 
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ME). Mice were housed in specific pathogen-free conditions, where all bedding, caging 
and feed were sterilized prior to use.  All mice underwent a 48-72 hour adjustment period 
after arrival before the enrollment in any experimental protocol.  
6.2.3 Synthesis  
6.2.3.1 Polyanhydride Nanoparticle Synthesis 
Polyanhydride particles were synthesized by anti-solvent nanoencapsulation as 
described previously (14, 15). Prior to encapsulation, endotoxin was removed from ova 
using Pierce
TM
 High Capacity Endotoxin Removal Spin Columns and quantified by 
Pierce
TM 
LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher Scientific, 
Waltham, MA). Protein was considered to be “endotoxin-free” below 0.01 ng/mL and 
encapsulated into nanoparticles for immunization. Briefly, either 20:80 CPH:SA or 
Poly(SA) (20mg/mL) were dissolved in methylene chloride with ova (5 wt%) and Span80 
® (1% v/v). The polymer solution was sonicated at 50 Hz for 30 seconds using a probe 
sonicator (Fisher Scientific Model 50 Sonic Dismembrator), then rapidly poured into a 
pentane bath at a solvent to non-solvent ratio of 1:250. Particles were collected by 
vacuum filtration (Whatman 50, Fisher Scientific), and characterized using scanning 
electron microscopy (SEM, Zeiss Supra40 Scanning Electron Microscope, Oberkochen, 
Germany).  
6.2.3.2 PROMPT Composite Microgel Synthesis 
Antisolvent precipitation was used to produce particle dispersions of 
polyanhydride nanoparticles stabilized by P(MAA-g-EG). P(MAA-g-EG) dissolved in 
deionized water (pH 6) at 20 mg/mL. Polyanhydride nanoparticles were added at 20 wt% 
relative to P(MAA-g-EG), and sonicated at 50 Hz for 30 seconds to achieve a dispersed 
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solution. The anti-solvent 0.1N HCl was used at a volumetric ratio of 1:100. Upon 
addition of solvent into the antisolvent phase, particles rapidly form and begin to 
flocculate.  
Flocs were collected by centrifugation (4500 rcf x 5 min), then freeze-dried. The 
final particles were obtained by crushing the particle pellet with a mortar and pestle to 
achieve a fine powder. PROMPT formulations are denoted in this work as either 
PROMPT 20:80 CPH:SA or PROMPT Poly(SA) based on the nanoparticle cargo.  
6.2.4 Mouse treatment  
6.2.4.1 Oral administration of particle formulations 
Female Balb/c mice, ages 6-8 weeks old, were immunized by oral gavage after a 
two hour fasting period. The oral gavage procedure was performed using a curved, 
stainless steel, 1.5”, 22-guage needle with a 2.4 mm ball tip (Squirrel Store, Alabaster, 
AL), with a maximum dosing volume of 10 mL/kg, or 200 μL per mouse. Prior to 
administration, the gavage needle was dipped into a 1 g/mL sucrose solution to minimize 
rodent stress during the procedure (16). After gavage, the mice were observed for 5-10 
minutes for any symptoms of respiratory distress.  Treatment groups consisted of 6 mice 
dosed with ova encapsulated into 5 mg PROMPT formulations, 1mg nanoparticles, or as 
a soluble dose suspended in 10X PBS. Control mice received PBS alone.  
 
6.2.4.2 Saphenous Vein Blood Collection 
Blood samples to evaluate the cytokine secretion and serum IgG were collected 
prior to immunization, at 24 and 72 hours post-immunization, and then weekly thereafter 
for the duration of the study in order to evaluate cytokine secretion and serum IgG. Blood 
was collected from the saphenous vein by gently restraining the animals and 
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immobilizing the hind leg, which was shaved to expose the saphenous vein. A sterile 23-
gauge needle was used to puncture the saphenous vein and the blood was collected using 
heparin coated capillary tubes. Collected blood was allowed to clot in low adhesion 
microcentrifuge tubes on ice for one hour.  Serum was then collected by centrifuging 
samples at 10,000 x g for 10 minutes. The collected serum removed and stored at -80
o
C 
until analysis.   
6.2.4.3 Fecal Pellet Collection 
Feces from each mouse were collected at weeks 4 and 8.  Seven fecal pellets were 
collected per mouse and dried overnight. Pellets were emulsified in 600 µl of ice-cold 
PBS containing 0.2 mg/mL trypsin inhibitor, 1% (w/v) bovine serum albumin, 25 mM 
EDTA and 0.035mg/mL Pefabloc in PBS and 50% glycerol at 4
o
C overnight. Debris was 
removed by centrifugation at 15,000 g for 10 minutes and supernatant collected and 
stored at -20
o
C.  
6.2.4.4 Intestinal Lavage 
Intestinal fluids were collected by a method adapted from Lycke, et al (17). The 
small intestine from the stomach to the cecum was removed and clamped on one end. The 
intestines were carefully injected with 3mL of a protease inhibitor solution consisting of 
0.1 mg/mL trypsin inhibitor, 50mM EDTA and 1mM PMSF in PBS, before clamping the 
other end of the intestine and incubating for 10 minutes at room temperature. The 
intestinal content was transferred to a test tube, vigorously vortexed, and then centrifuged 
for 10 min at 2000 rcf. The supernatant was transferred to microcentrifuge tubes and 
sodium azide was added to a total concentration of 0.001%. The mixture was incubated 
  
139 
for 15 minutes before addition of 50 µL goat serum per mL of solution, and then stored at 
-80
o
C until analysis.  
6.2.5 ELISA for Ova-specific IgG Antibody Titer  
High-binding 96-well plates (Costar 3590) were coated with 5μg/mL ova 
overnight at 4
o
C. Plates were washed with phosphate buffered saline containing 0.5% 
Tween 20 at a pH of 7.4 (PBST). Plates were blocked with 2% gelatin for two hours at 
room temperature and then washed again three times with PBST. Serial dilutions of 
serum samples in PBST with 1% heat inactivated normal goat serum were incubated 
overnight at 4
o
C. Plates were washed four times prior to addition of alkaline phosphatase-
conjugated AffiniPure goat anti-mouse IgG (H&L), (Jackson ImmunoResearch 
Laboratories, West Grove, PA) diluted 1:1000 in PBST with 1% heat inactivated normal 
goat serum for two hours at room temperature. Plates were washed four times with PBST 
and 100 µL p-nitrophenyl phosphate substrate (1 mg/mL) in diethanolamine substrate 
buffer was added to each well. Changes in optical density were measured at 405 nm using 
a Biotek Cytation 3 Cell Imaging Multi-Mode Reader (Winoosky, VT, USA).  
6.2.6 Mucosal Antibody (IgA) Determination 
High-binding 96-well plates (Costar 3590) were coated with 5 μg/mL ova 
overnight at 4
o
C. Plates were washed with PBST, blocked with 2% gelatin for two hours 
at room temperature, and then washed again three times with PBST. Serial dilutions of 
either fecal pellet or intestinal lavage samples diluted in PBST were incubated overnight 
at 4
o
C. Plates were washed four times prior to a two hour incubation with biotin rat anti-
mouse IgA diluted 1:2000 (Clone C10-1, BD Biosciences, San Jose, CA). Plates were 
washed and streptavidin-HRP diluted 1:1000 (BD Biosciences) incubated for two hours. 
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Plates were washed and color development achieved by addition of TMB substrate (BD 
Biosciences). Changes in optical density were measured at 405 nm using a Biotek 
Cytation 3 Cell Imaging Multi-Mode Reader (Winoosky, VT, USA). 
6.2.7 Assessment of Cytokine Levels 
Blood serum samples obtained 24 and 72 hours post-immunization were 
compared to baseline using a Bio-Plex Pro Mouse Cytokine Panel A 6-Plex assay (IL-1β, 
IL-6, IL-10, IL-17A IFN-γ, and TNF-α), per manufacturer’s instructions, and data 
acquired using a BioPlex200® Multiplex System (Bio-Rad, Hercules, CA).  
6.2.8 Histopathology 
Kidneys and liver were harvested and fixed in formalin. The tissues were sent to 
the University of Texas Health Science Center San Antonio (UTHSCSA) for paraffin 
embedding, sectioning and H&E staining. A blind histopathology analysis of the tissues 
was performed to assess both inflammatory markers and indications of organ failure, 
including tissue necrosis and distribution of inflammatory cells.  
6.2.9 Statistical Analysis 
Statistical analysis was used to analyze the cell surface marker expression and 
cytokine secretion data. Two-way ANOVA and Dunnett’s test were used to determine 
statistical significance among treatments and p-values <0.05 were considered significant. 
6.3 RESULTS AND DISCUSSION 
6.3.1 Ova-Specific Serum Antibody (IgG) Titers 
One of the primary benefits of vaccines administered via a mucosal route is the 
potential to elicit systemic immune protection in addition to the local mucosal response. 
Figure 6.1 shows the serum titers after oral immunization of mice by a single dose of ova 
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loaded into either nanoparticles alone (20:80 CPH:SA or Poly(SA)), or nanoparticles 
loaded at 20% feed ratio into composite PROMPT microgels (PROMPT 20:80 CPH:SA 
or PROMPT Poly(SA)). Soluble ova and PBS were included as controls. Anti-ova IgG 
response peaked at six weeks for PROMPT Poly(SA) composite microgels, in which 
serum IgG response was significantly higher than all other formulations. All other 
formulations, including soluble ova, failed to elicit ova-specific IgG titers above the 
baseline, as measured in mice treated with PBS only.  
Previous studies have demonstrated Poly(SA) chemistries are more rapidly 
internalized than more hydrophobic chemistries (18), which could be particularly 
beneficial in the narrow intestinal residence time. Additionally, it has been suggested that 
while hydrophobic chemistries can increase the association of nanoparticles with the 
mucosal barrier, this association could ultimately impede the necessary mucus 
penetration required for subsequent cellular uptake (19). The fact that PROMPT 
Poly(SA) induced a systemic immune response, while Poly(SA) nanoparticles did not, 
indicates that depot delivery achieved by microencapsulation can improve the response.  
It should be noted that while the theoretical loading of all formulations was 
matched at 50 μg/mL and encapsulated into either 1 mg of nanoparticles or 5mg of 
microgels, the  actual dosage of encapsulated ovalbumin depended on the encapsulation 
efficiency of the microgels and was, consequently, lower (see Chapter 4). Therefore, 
mice that received PROMPT Poly(SA) formulations actually received a dose of only 
approximately 13 µg of ova, instead of the 50 µg or 42 µg administered via soluble or 
nanoparticle-encapsulated doses, respectively. The difference in antigen ultimately 
delivered in PROMPT Poly(SA) as compared to Poly(SA) nanoparticles or soluble ova 
underscore the importance of a suitable oral delivery vehicle for effective immunization 
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using polyanhydride nanoparticles, as well as the potential dose-sparing capability of the 
composite materials.  
 
 
 
Figure 6.1 Ova-specific IgG in serum after single immunization of BALB/c mice (n=6 
±SEM; *p<0.05. Immunization was performed at day 0 by oral gavage of 
formulations containing 50 μg ova. Dashed lines indicate baseline levels 
detected by ova-specific ELISA in mice treated with PBS. 
 
6.3.2 Ova-Specific Intestinal Antibody (IgA) Titers 
The potential of PROMPT formulations to induce local mucosal immune response 
was evaluated in fecal pellet extractions obtained at weeks four and eight, as well as from 
intestinal fluid harvested at week eight (Figure 6.2). As observed for serum IgG analysis, 
only PROMPT Poly(SA) formulations induced statistically significant ova-specific IgA 
titers. PROMPT 20:80 CPH:SA also elicited detectable IgA levels at weeks four and 
either, while Poly(SA) nanoparticles alone elicited detectable IgA at week four which 
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dissipated by week eight. These results suggest that simple entrapment of antigen in 
nanoparticles was not sufficient for localized immune response. 
It is likely that the local dose of either soluble ova or nanoparticles alone in the 
intestine were two low to induce an immune response, which can lead to induction of 
tolerance rather than protection in the gastrointestinal mucosa (20, 21). PROMPT 
microgels, conversely, appear to facilitate mucosal antibody production. It is likely that 
microgel delivery enables a bolus dose of nanoparticles upon transit to the small intestine, 
which achieves a dose in the appropriate range for protective response. Additionally, the 
presence of PEG tethers in the P(MAA-g-EG) coating could provide advantages to 
facilitate nanoparticle interaction with GI mucosal surfaces,  increasing both residence 
time and local proximity (22, 23).   
However, encapsulation of the nanoparticles in P(MAA-g-EG) alone is not 
enough to elicit the desired response. While the PROMPT 20:80 CPH:SA formulation 
provided small and sustained IgA production, it did not achieve the significant immune 
response observed in PROMPT Poly(SA). Therefore, the chemistry of the nanoparticles 
themselves plays a key role in the ultimate effectiveness of the formulation. The 
Poly(SA) chemistry, compared to the 20:80 CPH:SA, seems to be advantageous in 
generating a localized immune response. Studies on copolymers of poly(SA) and PEG 
have demonstrate ability to rapidly transport in mucus, which could be impaired by the 
presence of the hydrophobic CPH moieties (24).  
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Figure 6.2 Ova-specific IgA in (A) fecal pellet extract and (B) intestinal fluid after single 
immunization of BALB/c mice (n=6 ± SEM;*p<0.05). Immunization was 
performed at day 0 by oral gavage of formulations containing 50 μg ova. 
Dashed lines indicate baseline levels detected by ova-specific ELISA in 
mice treated with PBS.  
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6.3.3 Cytokine Release  
Development of vaccines that enhance immunogenicity while minimizing 
reactogenicity is an important consideration for development of adjuvants and delivery 
systems. Cytokines comprise a family of proteins that are critical in cellular signaling and 
regulation of host immune response to infection, inflammation and trauma (25, 26). 
Evaluating serum cytokines can provide valuable information about local and systemic 
inflammatory environment induced by vaccine adjuvant systems. Additionally, cytokine 
microenvironments play a large role in shaping the antigen-specific adaptive immune 
response, directing Th1 or Th2 bias (27). Cytokine production occurs within hours of 
stimulus and concentration quickly dissipates due to the short-circulating in vivo half-live 
(26). 
In order to evaluate the inflammatory response to administration of PROMPT 
formulations, blood serum concentration of pro-inflammatory cytokines (IL-1β, IL-6, 
TNF-α), anti-inflammatory cytokine (IL-10) and additional cytokines (IL-6, IL-17) were 
measured at 24 hours (Figure 6.3) and 72 hours (Figure 6.4) post-immunization. These 
time points were selected to capture information on systemic cytokine levels within the 
window of response time to the stimulus – immunization – and in which levels should 
return to baseline. Cytokine primary source, target and biological role are summarized in 
Table 6.1. 
Average cytokine concentration was slightly increased at 24 hours, as compared 
to 72 hours for IL-1β, IL-6, IL-10, and TNF-α, across all formulations and controls. This 
minor but universal increase in cytokines can be attributed to the stress of the oral gavage 
procedure itself. Additionally, cytokine concentration was not significantly different for 
any animals receiving formulations or control compared to baseline (t=0) pooled 
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measurements. Serum levels of IL-17A and IFN-γ were mostly below the detectable 
range. These results indicate that the PROMPT microgels do not possess significant 
immunomodulatory functions, nor do they cause immunotoxicity and are therefore safe 
oral delivery vehicles.  
Table 6.1. List of evaluated cytokines, their principal production source, primary activity, 
and broad grouping. Adapted from Zhang, et al. (28) Abbreviations: IL – 
interleukin, TNF – tumor necrosis factor, IFN –interferon, Th –helper T 
cells, NK– natural killer, MHC – major histology complex, DC – dendritic 
cell, APC – antigen presenting cell 
Cytokine Source Target Biological Role 
IL-1β Macrophages, 
monocytes, 
DCs 
Th, NK, and B cells Pro-inflammatory; Th cell 
stimulation, NK cell activation, 
B cell maturation and 
proliferation 
IL-6 Activated Th2 
Cells, APCs,  
Plasma cells, B cells Pro-inflammatory and anti-
inflammatory; Differentiation 
and antibody secretion 
IL-17A Th17 cells Monocytes, neutrophils Pro-inflammatory; induce 
cytokine production by 
epithelia, endothelia, fibroblasts 
IL-10 Th2 cells, 
CD8+ T and 
B cells, 
macrophages 
Macrophages, APC Anti-inflammatory; inhibits 
cytokine production, promotes 
B cell proliferation and 
antibody production, suppresses 
cellular immunity 
IFNγ Activated 
Th1, NK 
Macrophages and other 
cells 
Inhibitor of viral replication, 
cell proliferation and IL-5 
induced isotype switching 
TNFα Macrophages Tumor cells, 
macrophages 
Cytotoxicity, induction of 
cytokine secretion; 
inflammation and pain 
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Figure 6.3 Cytokine expression levels at time 0 and 24 hours after oral administration of 
vaccine formulations and controls. T=0 blood samples were pooled. (n=6) 
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Figure 6.4 Cytokine expression levels at time 0 and 72 hours after oral administration of 
vaccine formulations and controls. T=0 blood samples were pooled. (n=6) 
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6.3.4 Histopathology 
Polyanhydride nanoparticles have been demonstrated to persist in vivo following 
subcutaneous or intranasal administration, and depending on the route of administration, 
can distribute away from the administration site (29, 30). While increased biodistribution 
could be advantageous for more robust immune protection, accumulation of particles in 
the liver or kidney could prove detrimental to normal physiological processes.  Liver and 
kidney tissues were examined for evidence of necrosis, cellular alterations, or 
inflammation. Across all treatment groups, there was no evidence of acute inflammation. 
Rare tubular casts and cytoplasmic eosinophilia were present in all kidney samples, 
though any morphological changes were not associated with parenchymal changes to 
tubular epithelial cells and glomeruli. Similarly, there was evidence of rare and subtle 
changes in the liver tissues characterized by the presence of random small collections of 
lymphoid cells in the parenchyma and portal areas of the liver. However, these changes 
were attributed to normal aging as opposed to pathological findings (31).  Overall, the 
histological evaluation of mice administered the various particle formulations revealed 
normal histological features similar to those observed in saline controls.   
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Figure 6.5 Administration of PROMPT formulations did not induce any significant 
histological alterations in kidneys. All samples were evaluated for evidence 
of necrosis, cellular alterations, inflammation, and location and distribution 
of histological changes. Scale bar 10µm. 
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Figure 6.6 Administration of PROMPT formulations did not induce any significant 
histological alterations in the liver. All samples were evaluated for evidence 
of necrosis, cellular alterations, inflammation, and location and distribution 
of histological changes. Scale bar 10µm. 
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6.4 CONCLUSIONS 
 The potential of PROMPT composite microgels to serve as oral vaccine carriers 
was evaluated after a single immunization with the model antigen ova. PROMPT 
Poly(SA) particles were the only formulation to induce systemic ova-specific IgG 
production. More promising, both PROMPT formulations induced measurable mucosal 
ova-specific IgA in both fecal matter and intestinal washes, with PROMPT Poly(SA) 
eliciting significantly higher IgA production compared to soluble ova, nanoparticles 
alone, or PROMPT 20:80 CPH:SA. The trend of IgA production observed after 
administration of PROMPT formulations support the benefits of microgel encapsulation 
of nanoparticles for effective local mucosal protection. Furthermore, formulations 
containing Poly(SA) demonstrate more promise than 20:80 CPH:SA formulations for IgA 
production.   
Cytokine levels measured after formulation administration showed no significant 
changes in expression to indicate inflammatory response, indicating the potential for 
these formulations to induce protective immune response without systemic 
reactogenicity. Additionally, histopathological evaluation of kidney and liver 
demonstrated no evidence of inflammation. Overall, these studies indicate that PROMPT 
microgel formulations warrant further study towards development of an adaptable oral 
vaccine platform with subunit antigen.  
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Chapter 7: Conclusions and Recommendations for Future Research  
7.1 CONCLUSIONS 
Oral vaccination represents the most attractive mode of administration due to the 
fact that oral delivery is noninvasive and safe, improving both patient compliance and 
clinical practicality. Oral delivery has also been demonstrated to enhance the mucosal 
immune response for improved local protection against pathogens that invade via the gut 
(e.g. enteropathogens). However, there are relatively few vaccines available via the oral 
route, and no oral vaccine formulations based on subunit vaccines. The challenges to 
development of oral formulations are attributed to i) the obstacles for a vaccine, 
particularly a protein or peptide, in the harsh environment of the gastrointestinal (GI) 
tract, including acidic pH and digestive enzymes; and ii) crossing the tightly regulated 
epithelial layer to enter the gut-associated lymphoid tissue where the mucosal immune 
responses may be induced.   
Development of polymeric nanoparticles for subunit vaccine delivery is a 
promising strategy. Nanoparticles afford protection of the antigen from degradation or 
clearance, can increase cellular uptake by inclusion of pathogen-mimicking 
characteristics (e.g. size, shape), and can be targeted to antigen presenting cells. 
However, formulating technology that enables oral vaccination in the gut remains a 
substantial challenge. Nanoparticle technologies still have limitations such as poor 
aqueous solubility, burst release, and insufficient protection of the encapsulated antigen. 
One strategy to improve the efficacy of nanoparticle-based vaccines is adding a 
polymeric coating, which can improve nanoparticle stability in contact with physiological 
fluids in the gastrointestinal tract and minimize premature release of the antigen (1-5).  
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The goal of this work was to develop, synthesize and characterize a composite 
approach to achieve oral delivery of nanoparticle-based vaccines.  Specifically, 
polyanhydride nanoparticles based on poly(sebacic acid) (SA) and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) have been developed by Professor Balaji Narasimhan 
and his research team at Iowa State University for use as vaccine platforms via 
subcutaneous or intranasal administration (6-10). These nanoparticles have demonstrated 
the ability to stabilize encapsulated antigens, sustain protein release, and stimulate 
humoral and cellular response. The Peppas lab has developed a class of pH-responsive 
hydrogels to protect sensitive therapeutics for oral delivery (11, 12). However, these 
networks are limited to delivery of low molecular weight macromolecules due to 
limitations in the mesh size. 
Inspired by the use of crosslinked hydrogel networks for pH-sensitive protein 
delivery, polyanionic microgels were synthesized using copolymers of methacrylic acid 
(MAA) and poly(ethylene glycol) monomethyl ether monomethacrylate (PEGMMA), 
denoted as P(MAA-g-EG). Microencapsulation of the nanoparticles was done via pH-
triggered self-assembly. In contrast to crosslinked networks, the self-assembly process 
enabled facile inclusion of nanoparticles without subsequent purification steps and 
overcame the limitations of release associated with crosslinked networks. The composite 
particles are called Polyanhydride-Releasing Oral MicroParticle Technology, or 
PROMPT.  
Several formulations were synthesized by varying the feed ratios of the 
polyanhydride nanoparticles and exploring two different polyanhydride compositions: 
Poly(SA) and 20:80 CPH:SA. The composition and molecular weight of P(MAA-g-EG) 
were verified by 
13
C NMR and GPC, respectively, prior to PROMPT synthesis. SEM 
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micrographs demonstrated the self-assembly process produced a polydisperse population 
of microgels with nanoparticles adsorbed to the surface, while confocal microscopy 
confirmed nanoparticle inclusion throughout the microgel. FT-IR further confirmed the 
inclusion of complexed P(MAA-g-EG) and nanoparticles into the PROMPT 
microparticles. The feed ratio of nanoparticles had a significant effect on the inclusion of 
the more hydrophobic 20:80 CPH:SA nanoparticles, but not Poly(SA). Both fluorescence 
and brightfield microscopy verified pH-dependent dissociation occurred rapidly upon 
transition from acidic to neutral pH environments.  
The suitability of PROMPT formulations for oral administration was assessed in 
release studies using the model antigen, ovalbumin. Poly(SA) nanoparticles had higher 
encapsulation efficiency than 20:80 CPH:SA, as well as slightly higher burst release, 
though both compositions demonstrated an initial burst of 60-70% and then sustained 
antigen delivery thereafter. All of the PROMPT formulations demonstrated reduced burst 
release compared to the nanoparticles alone, resulting in less than 50% cumulative mass 
fraction released. These results demonstrated that protection by P(MAA-g-EG) 
microencapsulation has the potential to slow the solvent diffusion to nanoparticles, 
thereby mitigating the degree of burst release and enabling a more sustained delivery of 
antigen. Formulations synthesized with a 20% feed ratio of nanoparticles exhibited lower 
fractional burst release compared to those synthesized with 10% feed ratio, attributed to 
the higher P(MAA-g-EG) content per mass facilitating more rapid dissociation of the 
microgels.  
In dynamic experiments mimicking gastrointestinal conditions, PROMPT 
formulations released negligible ovalbumin in gastric conditions. Upon transition to 
intestinal conditions, PROMPT formulations exhibited sustained release kinetics after the 
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initial burst of protein. Microgels synthesized with 20% feed ratio of nanoparticles 
released more protein than the 10% microgels. Additionally, 20:80 CPH:SA containing 
formulations released more ova than Poly(SA) microgels at the same feed ratio. 
Therefore, the increased incorporation efficiency for 20:80 CPH:SA into microgels offset 
both the lower encapsulation efficiency of ova into the nanoparticles and the slower 
release kinetics of the more hydrophobic 20:80 CPH:SA chemistry. 
Upon confirming that PROMPT formulations could release the nanoparticles and 
antigen in pH-dependent manner, their biocompatibility was studied in vitro using two 
representative cell lines: Caco-2 intestinal epithelial cells and RAW 264.7 macrophages. 
There was minimal effect on cellular proliferation or membrane integrity at 
concentrations up to 1mg/mL during the incubation with Caco-2 cells. Concentration-
dependent perturbation of cellular proliferation was observed when incubated with RAW 
264.7 macrophages for 24 hours, though these effects were attributed to the static nature 
of the cell culture conditions affecting nutrient exchange. However, there were no 
deleterious effects on cellular proliferation at lower concentrations, and no impact on 
membrane integrity for the extended incubation period.  
The capability of PROMPT formulations to stimulate antigen presenting cells was 
evaluated with bone marrow-derived dendritic cells. PROMPT formulations synthesized 
with 20% feed ratio of nanoparticles result in higher nanoparticle internalization as well 
as higher cell surface marker expression than those synthesized with 10% feed ratio of 
nanoparticles. Immunostimulatory capability was further confirmed by cytokine 
secretion, although no clear trends emerged regarding the nanoparticle composition or 
feed ratio into PROMPT microparticles.  
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An in vivo assessment of PROMPT formulations was performed to determine the 
ability to elicit systemic and mucosal immune response after oral administration. The 
20% PROMPT formulations were selected due to the higher total antigen loading and 
lower burst release.  Only the PROMPT Poly(SA) formulation induced statistically 
significant titers for both serum IgG and mucosal IgA, while both PROMPT formulations 
induced measurable IgA titers compared to the controls of soluble ova or nanoparticles 
alone. These results are particularly promising given that while the theoretical loading of 
all formulations was matched at 50 μg, the actual dosage of ovalbumin encapsulated 
depended on the encapsulation efficiency of the microgels and was, consequently, much 
lower. Therefore, the capability of PROMPT formulations to induce antibody production 
at a lower dose of encapsulated antigen than the nanoparticles underscore the importance 
of a suitable oral delivery vehicle for effective immunization using polyanhydride 
nanoparticles, as well as the potential dose-sparing capability of the composite materials. 
Furthermore, both analysis of cytokine profile and histopathological analysis of liver and 
kidneys indicate PROMPT formulations did not induce any damage or chronic 
inflammation.   
 In summary, a novel composite system was developed based on pH-responsive 
microencapsulation of polyanhydride nanoparticles. Synthesis of PROMPT formulations 
by self-assembly enabled facile synthesis of composite microparticles that did not require 
additional purification steps, readily incorporated two different polyanhydride 
compositions, and demonstrated rapid pH-dependent dissociation for depot release of the 
nanoparticle payload. Higher nanoparticle content in PROMPT microparticles was 
favorable for reduced burst release of the encapsulated antigen, higher total antigen 
loading, as well as increased cell surface marker expression. Additionally, 
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microencapsulation of polyanhydride nanoparticle was necessary to induce both serum 
IgG and mucosal IgA responses. These composite formulations have potential as a 
vehicle for oral vaccination with subunit antigens.  
 
7.2 RECOMMENDATIONS FOR FUTURE RESEARCH  
Future work on these systems could be directed towards more controlled self-
assembly. For example, the synthesis of block copolymers of MAA and PEG could allow 
for micellization and, therefore, more ordered morphology of the resulting microparticles. 
The ionizable MAA blocks should still form a hydrophobic core in acidic pH for 
inclusion of nanoparticles, with hydrophilic PEG blocks in the corona to minimize 
nanoparticle adhesion to the surface. Self-assembly of the amphiphilic block copolymers 
would enable more complete microencapsulation of the nanoparticles to further minimize 
the burst release associated with nanoparticles. There is currently ongoing work in the lab 
towards development of block co-polymers for self-assembly. 
 Additionally, the nature of the self-assembly process allows for facile co-
encapsulation of additional molecules, which has been demonstrated in pilot experiments 
with retinoic acid (data not shown). This could allow for inclusion and exploration of 
costimulatory molecules or mucosal adjuvants in future work.  
Alternative polyanhydride nanoparticle chemistries could be explored, since 
nanoparticle chemistry had an effect on both the microparticle encapsulation efficiency 
and immunomodulatory capabilities. For example, despite the 20:80 CPH:SA based 
PROMPT formulations demonstrating higher nanoparticle incorporation and, therefore, 
higher total antigen dose, the Poly(SA)-based PROMPT formulation elicited higher 
protective antibody titers in vivo. It is possible that the hydrophobicity of the 20:80 
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CPH:SA nanoparticles impaired mucus penetration and cellular internalization. 
Therefore, it could be desirable to explore other more amphiphilic polyanhydride 
chemistries. For example, copolymers including 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) (e.g. 20:80 CPHTEG:CPH and 50:50 CPTEG:CPH) have been 
demonstrated to stimulate strong cellular and humoral responses (13-15). 
The in vivo evaluation of these systems could be enhanced by inclusion of a 
higher dose of ovalbumin or using alternative immunization schedules. Ideally, these 
formulations would enable single dose immunization. However, including co-
administration of soluble antigen with the particles or administration of a “booster” dose 
would likely stimulate higher antibody titers in order to better compare the protective 
response elicited by the various formulation compositions. Evaluation of immune 
response could also be expanded to evaluate activation of T cells, which are critical in 
induction of high-affinity antibodies and immune memory. 
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Appendix A. Development of hydrolytically degradable hydrogel 
carriers for targeted intestinal release 
A.1 INTRODUCTION 
Development of biodegradable crosslinked hydrogels are of particular interest for 
drug delivery applications, particularly in consideration of larger payloads whose 
diffusion into and out of the network could be prohibited by maximum achievable mesh 
size. There are a number of strategies to incorporate biodegradable cleavage points. 
Ultimately, the choice of the appropriate labile chemistry within the crosslinking agent 
allows for the network to respond in a predictable manner to the environmental stimuli of 
interest, providing advantages for regulated release and/or targeted delivery of 
encapsulated payloads. For example, photolabile crosslinks enable externally triggered 
degradation (1, 2)), while inclusion of azoaromatic crosslinking agents or certain peptide 
sequences allow for degradation in the presence of specific enzymes in either site or 
disease specific manner (3-6). 
There are number of pH-responsive degradable cross linkers described in the 
literature for drug delivery applications. For example, acid-labile acetal crosslinkers 
allow for selective delivery of therapeutic content intracellularly in disease states such as 
tumors and inflammatory tissues (7).  There are also base-labile crosslinkers based on 
ester, amide or carbonate linkages, though degradation time at physiological pH is often 
on the order of days or weeks (8) (9). 
The chemical crosslinker, N,O-dimethacryloyl hydroxylamine (DMHA), is a 
base-labile crosslinking agent of interest for degradation in physiological conditions. 
DMHA undergoes hydrolysis above pH 5 and is stable below that pH. It has been 
explored for the development of biodegradable drug carriers, demonstrating capability to 
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improve delivery of both encapsulated low molecular weight and macromolecular drugs 
(10-14).  
This work explores the inclusion of DMHA in pH-responsive anionic 
poly(methacrylic acid-grafted-polyethylene glycol), or P(MAA-g-EG), hydrogel particles 
for a composite oral delivery system of nanoparticle vaccines.  
A.2 EXPERIMENTAL METHODS 
A.2.1 Materials  
All reagents were used as received. Methacrylic acid (MAA) and 1-
hydroxycyclohexyl phenyl ketone (Irgacure® 184) were obtained from Sigma-Aldrich 
(St.Louis, MO). Polyethylene glycol monomethyl ether methacrylate (PEGMMA, ME 
1000) was purchased from Polysciences Inc. (Warrington, PA). All other solvents and 
buffers were also obtained from Thermo Fisher Scientific (Waltham, MA).  
A.2.2 Synthesis of N,O- Dimethacryloylhydroxylamine 
DMHA was graciously prepared by the laboratory of Professor Emmanuel Akala 
at Howard University, as published previously and demonstrated in Figure A.1 (11-13). 
Briefly, DMHA is formed from methacryloylation of hydroxylamine. In a typical 
synthesis, hydroxylamine hydrochloride (2.5 g, 0.036 mol) was dissolved in pyridine 
(26.1 mL, 0.3298 mol).  Methacryloyl chloride (8.3 mL, 0.085 mol) was added dropwise 
with a syringe while the reaction was maintained by an ice bath. After addition of the 
methacryloyl chloride, the reaction was allowed to proceed for two hours at room 
temperature.  After the reaction period, chloroform (28.4 mL) was added and the 
resulting solution was washed twice with distilled water, dried with anhydrous 
magnesium sulphate and evaporated under vacuum to obtain a solid crystalline material. 
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Purification of the crystals was carried out by the addition of cold hexane and 
ethylacetate (5:1) to the solid and placed in the freezer for 1 hour. White crystals were 
recovered by vacuum filtration. 
 
 
Figure A.1 Preparation of hydolyzable crosslinking agent DMHA by the reaction of 
hydroxylamine hydrochloride with methacryoyl chloride in pyridine.  
A.2.3 Characterization of DMHA crosslinking agent 
Fourier-transform infrared (FT-IR) spectrophotometric analysis was used to verify 
structure of DMHA crosslinking agent by averaging 64 scans on a Nicolet iS10 FT-IR 
Spectrometer (Thermo Fisher Scientitifiec, Waltham, MA, USA) outfitted with Smart 
iTX accessory for measurement in ATR mode. Proton nuclear magnetic resonance (
1
H-
NMR) using a VARIAN DirectDrive 400 MHZ spectrophotometer. DMHA samples 
were dissolved at 15 mg/mL in deuterated dimethyl sulfoxide.    
A.2.4 Polyanhydride Nanoparticle Synthesis 
Polyanhydride particles were synthesized by anti-solvent nanoencapsulation as 
described previously (15, 16). For these studies 20:80 CPH:SA (20 mg/mL) was 
dissolved in methylene chloride with Span® 80 (1% v/v) and quantum dots (λem= 625 
nm) (1% v/v).  The polymer solution was sonicated at 50 Hz for 30 seconds using a probe 
sonicator (Fisher Scientific Model 50 Sonic Dismembrator) and then rapidly poured into 
a pentane bath at a solvent to non-solvent ratio of 1:250. Resulting particles were 
collected by filtration (Whatman 50, Fisher Scientific).  
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A.2.5 Synthesis of hydrolytically degradable hydrogel carriers for targeted intestinal 
delivery 
Hydrolyzable networks were synthesized by photoinitiated, free-radical 
polymerization of monomer solutions containing MAA, PEGMMA, and DMHA.  MAA 
and PEGMMA were mixed in a 1:1 molar ratio in 1:1 (w/w) deionized water and ethanol 
solution to yield a 1:1 (w/w) total monomer to solvent ratio. The photoinitiator Irgacure® 
184 was added at 1 wt% with respect to total monomer weight. DMHA was added in 
10% (by volume) solution of DMSO at crosslinking densities between 0.5-2 mol% 
relative to total monomer content. The mixture was homogenized by sonication, loaded 
into the sealed and oxygen-deficient environment of an MBraun® glovebox (MBraun 
Inc., Garching, Germany), and purged with nitrogen for 5 minutes. Finally, the solution 
was pipetted between glass slides, separated by a 0.7 mm Teflon® spacer, and placed into 
a UV flood source at 70% intensity for 30 minutes.  
Following polymerization, the film was removed from the slides and either 
punched into discs (6mm diameter) or left as a bulk film for purification and drying. 
Hydrogels were purified from unreacted reagents by washes in ethanol (5 washes with 
solution changes every 30 minutes), and then gradually transitioned to aqueous solution 
(0.01M HCl, pH 2.0) for the next 5 washes at 30 minutes intervals. Finally, dried bulk 
films were crushed into microparticles using a mortar and pestle and sieved into distinct 
size ranges, ranging from ~30-90 µm, and stored in a desiccator at room temperature. As 
an experimental control, P(MAA-g-EG) hydrogels were synthesized with the non-
degradable crosslinker tetraethyleneglycol dimethacrylate (TEGDMA) at 0.75 mol% and 
prepared in the same manner.  
Synthesis was slightly modified for inclusion of polyanhydride nanoparticles into 
the hydrogel matrix. Briefly, nanoparticles were incorporated into the pre-polymer 
  
170 
solution at 5-20% by weight with respect to total precursor concentration. The solution 
was homogenized by sonication for 5-10 minutes, followed by polymerization steps 
described previously and ultimate crushing of microparticles containing nanoparticles.  
A.2.6 Relative turbidity degradation studies 
Turbidity measurements were used to evaluate the time-dependent degradation of 
microparticles. Microgels (90-150 μm) were suspended in either 1X phosphate buffered 
saline (PBS) or 0.1N hydrochloric acid (HCl) at a concentration of 5 mg/mL. One 
hundred microliters of each sample solution was added to a 96-well plate in triplicate and 
absorbance was measured at 250 nm at two minute intervals over the course of 90 
minutes using a Cytation 3 Cell Imaging Multi-Mode Reader (BioTek, Winooski, VT). 
Statistical analysis was performed to compare formulations using ANOVA to compare 
multiple groups and post-hoc Dunnett’s test to confirm statistical significance, with p-
values < 0.05 considered significant. 
A.2.7 Microparticle morphology 
Scanning electron microscopy (SEM) was used to examine the surface 
morphology, particle shape, and size of microparticle formulations in the dried state. 
Microparticles were examined at various time points after incubation in PBS (pH 7.4) to 
evaluate degradation over time. After samples were exposed to PBS for the designated 
amount of time, 1N hydrochloric acid was added dropwise until the solution reached a 
pH of 2 and remaining particles were collapsed. Particles were collected by 
centrifugation and then re-suspended in ethanol. SEM stubs were prepared using a drop-
casting technique, dried, and then coated with 8nm of platinum/palladium using a 
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Cressington 208HR sputter coater (Watford, England, UK). Coated samples were imaged 
with a Zeiss Supra 40VP Scanning Electron Microscope (Oberkochen, Germany).  
A.2.8 pH-dependent hydrolytic degradation studies 
Gravimetric degradation experiments were carried out to observe the rate of 
hydrolytic degradation as a function of DMHA crosslinking density. Hydrogel discs 
(6mm) were dried in a vacuum oven were weighed (Mo) and placed into 37
o
C PBS (pH 
7.4). At each time point, samples were removed, freeze dried, and then weighed to 
determine fraction of initial mass remaining (Mt/Mo). Triplicate samples were used for 
each time point.  
A.2.9 Verification of Nanoparticle Incorporation  
Fluorescence microscopy was used to verify successful incorporation of 
nanoparticles (encapsulating quantum dots) into the hydrogel network. Nanoparticle 
distribution in the microgel population was determined by ImageStream®X Mark II 
Imaging Flow Cytometer (EMD Millipore, Darmstadt, Germany).  
 
A.3. RESULTS AND DISCUSSION 
A.3.1 DMHA Characterization 
Both the FT-IR and 
1
H NMR spectra of the crosslinking agent DMHA were 
consistent with the expected structure and those previously reported (11, 17).  The FT-IR 
spectrum shows the presence of C=C stretch at 1626 cm
−1
, as well as both ester and 
amide C=0 stretches at 1766 cm
−1
 and 1663 cm
−1
, respectively. The proton NMR 
spectrum confirms the presence of a divinylic structure, and is consistent with previously 
published structures 
1
H NMR (400 MHz, C2D6OS) δ 1.86 [s, 3H, CH2=C(CH3)CO-NH-
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O-CO-C(CH3)=CH2] 1.93 [s, 3H, CH2=C(CH3)CO-NH-COC(CH3)=CH2], 5.48 [s, 1H, 
CH2=C(CH3)CO-NH-CO-C(CH3)=CH2] 5.72 [s, 1H,CH2=C(CH3)CO-NH-CO-
C(CH3)=CH2] 5.85 [s, 1H, CH2=C(CH3)CO-NH-COC(CH3)=CH2] 6.16 [s, 1H, 
CH2=C(CH3)CO-NH-CO-C(CH3)=CH2] 9.20 [s, 1H, CH2=C(CH3)CO-NH-CO-
C(CH3)=CH2]. Characterization was performed for every batch of DMHA received, as 
well as for polymerizations after long periods of DMHA storage to ensure the crosslinker 
remained intact.  Representative spectra are depicted in Figures A.2 and A.3 
 
 
 
 
Figure A.2 Proton NMR spectrum of DMHA crosslinker (400 MHz, C2D6OS) 
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Figure A.3 Representative FTIR spectra of DMHA crosslinker.  
 
A.3.2   Turbidimetric Measurements 
Turbidity measurements are often used to evaluate temperature-dependent phase 
transitions of thermoresponsive polymers such as poly(N-isopropylacrylamide) (18, 19). 
More recently, turbidity has been used to measure evaluate degradation of particles as a 
function of time (6, 20). As reported by Klinger and Landfester (20), decreased turbidity 
over time is observed as the network loosens, swelling of the gel increases and the 
contrast between the refractive indices of the solvent and the polymer decreases. 
Mathematically, turbidity is described by the following equation (21): 
 
𝜏 =
𝜑𝑄𝑒𝑥𝑡3
2𝑑
 (Equation A.1) 
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Where 𝜑 is the volume fraction of the particles, 𝑄𝑒𝑥𝑡 is the Mie extinction 
efficiency, and d is the particle diameter. 𝑄𝑒𝑥𝑡 is a function of both particle size and the 
ratio of the refractive indices of the particles and the solvent, np/n0, and decreases as either 
of those parameters decrease.  
It was hypothesized that as crosslinking points were cleaved, resulting in smaller 
particles and eventually linear polymer, that turbidity would decrease over time 
correlating with the extent of degradation. Experimentally, turbidity was determined by 
measuring the absorbance of the degrading microgels at 250 nm, the peak absorbance for 
the incident light. Turbidity τ(t) was calculated as the intensity ratio of transmitted light 
of sample (It) to transmitted light of pure solvent (Io), as follows: 
 
𝜏(𝑡) =  − ln (
𝐼𝑡
𝐼0
) =  −ln (
10𝐴,𝑏𝑙𝑎𝑛𝑘)
10𝐴,𝑠𝑎𝑚𝑝𝑙𝑒
)  (Equation A.2) 
 
Relative turbidity enables better comparison between samples that vary in particle 
size and was calculated as: 
  
𝜏𝑟𝑒𝑙 =
𝜏(𝑡)
𝜏(𝑡=0)
∗ 100 (Equation A.3) 
 
and then plotted as a function of time.  
The turbidity of P(MAA-g-EG) 1%DMHA, 2%DMHA and 0.75%TEGDMA 
hydrogel microparticles (90-150 µm) at 5 mg/mL concentration were evaluated (Figure 
A.4). As expected, relative turbidity decreased for samples incubated in PBS with values 
plateauing after 20-40 minutes. However, differences between swelling and degradation 
were difficult to discern using this technique, as evidenced by the nearly identical trends 
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observed for 2%DMHA and non-degradable 0.75%TEGDMA microgels. The 1%DMHA 
microgels had statistically significant reduction in turbidity as compared to the other two 
formulations starting at 12 minutes, which could be attributed either to increased swelling 
capability associated with decreased crosslinking density or as degradation of the 
crosslinking points, or some combination of the two phenomena.  
 
 
Figure A.4 Relative turbidity of P(MAA-g-EG) microgel formulations prepared at 5 
mg/mL concentration in 1X phosphate buffered saline (37
o
C, pH 7.4 n=3 +/- 
S.E.M.) unless specified as 0.1M HCl (37
o
C, pH 1.2, n=3 +/- S.E.M). 
Absorbance readings were measured at 250 nm for 90 minutes.  
 
A.3.3 SEM 
Microparticle morphology of P(MAA-g-EG) microgels containing 2mol% 
DMHA were examined using SEM at various time points throughout the degradation 
process (Figure 6). Microgels crushed to 90-150 µm by mortar and pestle have irregular 
morphology. Figures 6 B) and C) show microgels after 5 and 24 hours of exposure to 
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degrading conditions (pH 7.4), respectively. However, it should be noted that since water 
must be used instead of PBS to prepare samples for SEM, swelling and deprotonation of 
MAA acidified the solution and slowed the pH dependent hydrolysis, indicated by 
minimal changes to particle morphology within 5 hours (Figure 6B). However, within 24 
hours, particles were substantially smaller than original particles (Figure 6C). 
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Figure A.5 Representative scanning electron microscopy (SEM) images of P(MAA-g-
EG) microgels containing 2 mol% DMHA at 150x magnification. A) Gels 
crushed to 90-150 µm by mortar and pestle have irregular morphology. B) 
and C) illustrate microgels after 5 and 24 hours of exposure to degrading 
conditions (pH 7.4), respectively. Particle morphology does not change 
substantially by 5 hours, but particles are substantially smaller fragments by 
24 hours. 
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A.3.4 Gravimetric Analysis 
Gravimetric analysis was used to determine how the hydrolytic degradation of the 
hydrogel network could be modulated by crosslinking density, with the goal of releasing 
the encapsulated payload within the relatively narrow residence time of 3-6 hours within 
the small intestine (22). It was expected that reducing the crosslinking density would 
result in faster degradation of the hydrogel networks, due to increased swelling capacity 
and fewer scission points (13).  
The expected trend was observed for DMHA crosslinking densities between 1 and 
4% (Figure A.6). The 4% gels burst into pieces within the first hour of submersion into 
degrading conditions, but maintained weight for the duration of the study thereafter. At 
lower crosslinking densities, the gels remained intact during initial swelling and slowly 
degraded over time, with the 1% gel degrading completely within 6 hours. While 6 hours 
exceeds the intestinal residence time, microparticles have a much larger surface area to 
volume ratio than the hydrogel discs and therefore are expected to degrade at faster 
timescales. 
 Interestingly, further reducing the crosslinking below 1% had the unexpected 
result of increasing the degradation time. Previous studies on degradable ionic hydrogel 
networks have demonstrated the complex behavior of degradable networks, noting 
deviation from theoretical predictions of macroscopic properties based on microscopic 
crosslinking density during late stages of degradation (23). These deviations have been 
attributed to chemical and structural changes occurring within the network, such as 
buildup of negatively charged carboxyl groups within the network that can expand and 
then stiffen the networks.  It is also possible that the longer polymer chains synthesized as 
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a result of the decreased crosslinking density physically hindered hydration of the 
network, and accordingly decreased the rate of crosslinker hydrolysis. 
In follow up studies to investigate the surprising result, a new batch of DMHA 
crosslinker was used to synthesize the hydrogels. Though similar trends were observed, 
the degradation time was inconsistent with previous experiments, increasing from 6 to 8 
hours for complete degradation of the 1% DMHA hydrogels and even longer for the 
0.75% DMHA hydrogels (Figure A.7). Though the chemical evaluation of the 
crosslinkers matched, the incorporation into the hydrogel matrix appeared to be different 
enough to affect the degradation time.  
 
 
 
Figure A.6. Degradation of hydrogel discs was measured as fraction mass remaining as a 
function of time in hydrolytic conditions (PBS, pH 7.4).  
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Figure A.7. Degradation of hydrogel discs measured as fraction mass remaining as a 
function of time for hydrogels composed with two different batches of 
DMHA.  
 
A.3.5 NANOPARTICLE INCORPORATION 
Both fluorescence microscopy and imaging flow cytometry were used to evaluate 
nanoparticle incorporation into the microgels. Fluorescence microscopy confirmed that 
nanoparticles were successfully encapsulated into the crushed microgels (Figure A.8). 
However, nanoparticles aggregated during the synthesis resulting in very unequal 
distribution of the nanoparticles within the microgel population. Imaging flow cytometry 
further confirmed nanoparticle aggregation affected nanoparticle distribution both within 
a single particle and among the particle populations. Figure A.9 demonstrates a 
representative population of P(MAA-g-EG) microgels synthesized with 20:80 CPH:SA 
nanoparticles at 20 wt% with respect to the monomer content.  On average, 64% of the 
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microgels contained “fluorescent events” indicative of nanoparticle incorporation, with 
fluorescence intensity varying substantially between individual microgels.   
 
 
 
 
Figure A.8 Fluorescent light microscopy verified nanoparticle incorporation into 
microgels. Scale bar: 100 μm 
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Figure A.9 Representative data from imaging flow cytometry of P(MAA-g-EG) 
microgels encapsulating 20:80 CPH:SA nanoparticles demonstrate that 64% 
of microgels encapsulate nanoparticles.  
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A.4. CONCLUSIONS 
 Biodegradable hydrogel films and microparticles were synthesized using the base-
labile crosslinker, DMHA.  The pH-dependent degradation of microgels was assessed by 
scanning electron microscopy and turbidity, though swelling and degradation behavior 
were indistinguishable in the latter. Gravimetric analysis confirmed degradation kinetics 
were tunable by modifying the crosslinking density. Hydrogels crosslinked with 1% 
DMHA degraded within the least amount of time, which is desirable for targeted delivery 
within the ~4 hour intestinal residence time.   However, the degradation kinetics were 
inconsistent between batches of the hydrolysable crosslinker. Furthermore, inclusion of 
the nanoparticles into microgels was variable due to aggregation during the 
polymerization process, resulting in an average of 64% microgels containing 
nanoparticles. In order to achieve targeted intestinal delivery of the nanoparticle vaccines, 
it is desirable to achieve complete degradation within the intestinal residence time to 
ensure release of the nanoparticles. Furthermore, microgel encapsulation of the 
nanoparticles needs to be more efficient and consistent for appropriate dosage 
calculations. Therefore, it was determined that inclusion of DMHA as a crosslinker was 
not a suitable strategy for oral delivery system of nanoparticle vaccines. 
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